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RIASSUNTO 
 
Introduzione. Il principio fisico dell’elettroporazione (EP) cellulare (la 
temporanea permeabilizzazione della membrana citoplasmatica per mezzo di 
campi elettrici) è stato applicato al trattamento dei tumori con l’intento di 
aumentare la concentrazione dei farmaci antiblastici (bleomicina e cisplatino) 
all’interno della cellula tumorale e, di conseguenza, la loro azione citotossica. 
Fino al 2006, anno di standardizzazione della procedura 
dell’elettrochemioterapia (ECT), l’esperienza clinica con questo tipo di 
trattamento era limitata ad alcuni studi di efficacia. 
 
Scopo. Lo scopo del progetto è stato quello di indagare l’efficacia dell’ECT in 
popolazioni omogenee di pazienti oncologici (pazienti con metastasi cutanee da 
melanoma, recidiva da carcinoma mammario sulla parete toracica, recidiva di 
sarcoma dei tessuti molli, tumori del distretto capo-collo). Inoltre, è stata 
indagata la fattibilità e l’efficacia di una nuova apparecchiatura, in grado di 
applicare il trattamento anche a tumori profondi. Infine, è stata indagata, a 
livello clinico e preclinico la possibilità di migliorare l’efficacia del trattamento 
tramite, rispettivamente, la valutazione degli effetti immunologici del 
trattamento (induzione dei Toll-like receptors, TLRs) e la valutazione 
dell’effetto  sensibilizzante della butionina sulfossimina (BSO) all’azione della 
bleomicina.  
 
Metodi. Complessivamente, sono stati disegnati quattro studi clinici prospettici 
di fase II, di cui tre conclusi ed uno attualmente in corso di arruolamento, ed 
uno retrospettivo. Inoltre, sono stati analizzati i campioni tessutali di alcuni 
pazienti prima e dopo il trattamento per analizzare i livelli di espressione dei 
TLRs. In fine, sono stati condotti degli studi su linee cellulari per valutare 
l’effetto sensibilizzante della BSO al trattamento con BLM + EP.  
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Risultati. In tutti gli istotipi tumorali trattati l’ECT ha dimostrato, a livello 
locale, un livello di attività superiore a quello dei regimi di chemioterapia 
attualmente impiegati. Questo si è tradotto in un apprezzabile controllo locale 
dei tumori trattati, a fronte di una tossicità limitata e perlopiù locale. 
Nei campioni tissutali prelevati prima e dopo il trattamento, la variazione dei 
livelli dei TLRs non è risultata significativa, ma un elevato infiltrato linfocitario 
nella lesione è risultato correlato con il grado di risposta locale. In vitro, il 
pretrattamento con BSO aumenta la citotossicità del trattamento con BLM + 
EP. Un risultato ancillare è stato anche il riscontro di un’ aumento della 
tossicità del melphalan, un farmaco attualmente impiegato nella terapia loco 
regionale del melanoma, in associazione all’EP. La applicazione clinica 
dell’ECT ha permesso di rilevare (anche grazie alla collaborazione 
multidisciplinare) alcuni aspetti tecnici (applicazione e gestione del campo 
elettrico sui tessuti) meritevoli di essere migliorati per aumentare l’efficacia del 
trattamento ed il numero di pazienti che possono beneficiarne.  
 
Conclusioni. L’ECT si è dimostrata un trattamento dotato di un’elevata attività 
nel trattamento delle recidive di melanoma, carcinoma mammario, sarcomi dei 
tessuti molli e tumori del distretto capo-collo. L’esperienza clinica iniziale con 
una nuova apparecchiatura ed elettrodi dedicati ha rilevato la possibilità di 
trattare efficacemente anche i tumori profondi. Il trattamento di ECT sembra 
non ha innalzato significativamente i livelli di TLRs nei tumori dei pazienti 
trattati, ma livelli elevati di infiltrato linfocitario nel tumore sono risultati 
correlati con livelli maggiori di risposta locale. La BSO è in grado di 
sensibilizzare in vitro i tumori al trattamento combinato con BLM ed EP. L’EP 
merita di essere ulteriormente indagata, anche in associazione al melphalan nei 
pazienti con melanoma. 
In conclusione, l’ECT ha la potenzialità di essere implementata in campo 
oncologico attraverso la collaborazione multidisciplinare di oncologo, chirurgo, 
radioterapista, biologo ed ingegnere.        
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ABSTRACT 
 
Introduction. The principle of cell electroporation (EP) (the temporary 
permeabilization of the cytoplasmatic membrane by means of electric fields) 
has been applied to the treatment of tumors with the intent of increasing the 
concentration of anticancer drugs (cisplatin and bleomycin) within the tumor 
cell and hence their cytotoxic effect. Until 2006, the year of standardization of 
the electrochemotherapy (ECT) procedure, clinical experience was limited to 
small heterogeneous series, mainly focused on local activity data in patients 
with superficial metastases.  
 
Aims. The aim of this project was to investigate the efficacy of ECT in 
homogeneous populations of cancer patients of different histotypes (patients 
with skin metastases from malignant melanoma, recurrent breast cancer on the 
chest wall, recurrent soft tissue sarcomas and tumors of the head and neck 
area). Furthermore, it was investigated the feasibility and efficacy of a new 
device (electric pulse generator and dedicated needle electrodes), capable of 
applying homogeneous electric fields also to deep tumors. Finally, we 
investigated, both at clinical and preclinical level, the possibility of improving 
the effectiveness of ECT by, respectively, the evaluation of some immune 
effect of treatment (i.e., the induction of the Toll-like receptors, TLRs) and the 
evaluation of the tumor sensitizing action to ECT of buthionine sulfoximine 
(BSO), an inhibitor of glutathione biosynthesis. 
 
Methods. Overall, four prospective, phase-II, clinical trials were designed, 
three of them have been concluded and a fourth is still ongoing and patients’ 
enrollment is open. Moreover, a retrospective study was performed on head and 
neck cancer patients. In some patients, tissue samples were analyzed before and 
after ECT, to evaluate the expression of TLRs. Finally, some in vitro tests were 
conducted on tumor cell lines to assess the sensitizing effect of BSO pre-
treatment to BLM + EP administration. 
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 Results. All the histotypes showed high local response rates and ECT activity 
was more pronounced than standard chemotherapy regimens employed in 
current oncology practice. Local response translated in an appreciable local 
control of the treated tumors, while toxicity was limited and mainly local. 
TLRs levels in post-ECT tumor biopsies was not significantly different, 
compared with pre-ECT samples. However, the immune reaction seems to play 
a role since a high lymphocytic infiltrate into the electroporated lesions was 
associated with higher response rates. In vitro tests, BSO pretreatment 
enhanced the cytotoxicity of BLM + EP. Of note, we also found an increased 
toxicity of melphalan, a drug currently used in the treatment of locoregional 
melanoma, in association with EPs. Thanks to the multi-disciplinary 
collaboration and clinical case management, we have individuated some 
technical aspects that deserve further improvement in order to increase the 
effectiveness of treatment application and the number of patients who can 
benefit from it. 
 
Conclusions. ECT has proved a highly active treatment in recurrent melanoma, 
breast cancer, soft tissue sarcomas and cancers of the head and neck region. 
The preliminary clinical experience with a new device and dedicated electrodes 
indicates the feasibility to treat percutaneously even large, deep-seated tumors. 
Although ECT treatment do not seem to raise the levels of TLRs in the 
electroporated tumors, however the levels of lymphocytic infiltration were 
associated with better local response. In vitro, BSO pre-treatment is able to 
sensitize tumor cells to the combined treatment of BLM and EP. 
Electroporation deserves further investigation also in combination with 
melphalan, which is currently used in locoregional chemotherapy of in transit 
metastases from melanoma. 
In conclusion, ECT has the potential to be implemented in the oncology field 
through the multidisciplinary collaboration of oncologists, surgeons, radiation 
oncologists, biologists and engineers. 
INTRODUCTION 
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ELECTROCHEMOTHERAPY (ECT): BASIC CONCEPTS 
 
The direct injection of therapeutic molecules into cells and tissues can be 
considered as the simplest method for drug delivery. However, the main 
drawback of this method is the low efficiency of drug bio-distribution and 
uptake. For 10 years now, the development of tumor-targeting and drug 
delivery methods in cancer treatment has become a major bio-medical research 
field in order to increase therapeutic benefits and reduce the side effects of 
therapeutic molecules. The common aspect of these methods is to deliver drugs 
into cells via plasma membrane modifications.  Drug-loaded chemical vectors 
fuse with the plasma membrane or are endocytosed by the cell. Physical 
methods transiently destabilize the plasma membrane creating leaky structures 
(e.g. membrane defects or pores). Among these methods, 
electropermeabilization (also named electroporation, EP) has received 
increasing attention, particularly as a promising method for drug delivery [1]. In 
the past 25 years, electropermeabilization has proved to be safe and efficient for 
the delivery of nucleic acids (e.g. plasmid DNA, siRNA, antisense RNA), 
proteins (e.g. antibody) and antitumor drugs (e.g. cisplatin [CDDP], bleomycin 
[BLM]) across the plasma membrane [2-4]. Electropermeabilization-based 
cancer treatment methods are currently undergoing intensive exploration in the 
field of drug delivery [5], gene therapy [6], genetic vaccination [7] and 
irreversible electroporation [8]. The first medical application in the treatment of 
cancer is electrochemotherapy (ECT), which became a clinically approved 
treatment approach for cutaneous and subcutaneous tumors [9−11]. ECT is 
defined as a local treatment, which, thanks to cell membrane permeabilizing 
electric pulses, potentiates the cytotoxicity of non- or poorly permeant anti-
tumor drugs [5].  
 
Physical principles 
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Electroporation is a method of cell membrane permeabilization that is today 
widely used in biotechnology and medicine for delivery of drugs and genes into 
living cells [12]. It is alternative method for water sterilization and food 
preservation [13], and it is a prerequisite for cell electrofusion. The 
phenomenon of electroporation can be described as a dramatic increase in 
membrane permeability caused by externally applied short and intense electric 
pulses. Various theoretical models were developed to describe electroporation, 
among which the transient aqueous pore model is the most widely accepted. 
According to this model, hydrophilic pores are formed in the lipid bilayer of a 
cell membrane when it is exposed to external electric pulses. In the cell 
membrane, hydrophobic pores are formed by spontaneous thermal fluctuations 
of membrane lipids. In a cell exposed to an external electric field, the presence 
of an induced transmembrane potential provides the free energy necessary for 
structural rearrangements of membrane phospholipids and thus enables 
hydrophilic pore formation. Hydrophilic pores form only in a small fraction of 
the membrane exposed to electric field. Even though some attempts to visualize 
the changes in the membrane structure caused by electric pulse application were 
made [14], the structural reorganization and creation of hydrophilic pores has 
so far not been directly observed. All the data available until now have been 
obtained as an indirect evidence of membrane permeabilization, such as 
measurements of conductivity changes caused by electric pulse application and 
observations of molecular transport through the cell membrane. Cell membrane 
electroporation takes place because the cell membrane amplifies the applied 
external electric field, as its conductivity is several orders of magnitude lower 
than the conductivities of extra cellular medium and cell cytoplasm. The 
theoretical description of the transmembrane potential induced on a spherical 
cell exposed to electric field is known as Schwan’s equation [15]. The induced 
transmembrane potential for a spherical cell can be calculated as: 
UTI = −1.5rEcosϕ 
where r is the radius of the cell, E is the strength of applied electric field, and ϕ 
is the angle between the direction of the electric field and the selected point on 
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the cell surface. The induced transmembrane potential and therefore maximum 
electroporation occur at the poles of the cell exposed to the electric field facing 
the electrodes (Fig. 1). Electroporation can be either reversible or irreversible, 
depending on parameters of the electric pulses. It is a threshold phenomenon: 
the induced trans membrane voltage imposed by external electric field should 
reach a critical value to trigger formation of transient aqueous pores in the cell 
membrane. The threshold membrane potential that needs to be reached in the 
cell membrane is between 200 mV and 1 V. For reversibility of electroporation, 
the membrane potential has to be kept below the critical value. In such 
conditions, the cell membrane recovers after electric pulse application. On the 
contrary, when the critical value is exceeded, irreversible electroporation takes 
place, resulting in cell membrane disintegration and loss of cell viability. The 
electroporation process consists of different phases. The first of them is pore 
formation, which is the cell membrane’s response to the induced threshold 
membrane potential, and lasts a few microseconds. The second phase is a time 
dependent expansion of the pore size taking place in a time range of hundreds 
of microseconds to milliseconds, and lasts throughout the duration of pulses. 
The last phase is membrane recovery, which takes place after electric pulse 
application and consists of pore resealing, and lasts several minutes This 
resealing phase is strongly affected by temperature and cytoskeleton integrity 
[16-17]. The first phase of electroporation can be measured by changes in 
membrane conductivity and is related to short-lived transient pore formation, 
which does not contribute to molecular transport [18]. Molecular transport 
across the permeabilized cell membrane associated with electroporation is 
observed from the pore formation phase until membrane resealing is completed 
[19]. Electroporated membranes are also a prerequisite for associated 
membrane 
phenomena termed electrofusion. During electric pulse application and 
immediately after it, the cell membrane is capable of fusion: it is in a so-called 
fusogenic state. In brief, electroporation is a useful technique in biotechnology 
and medicine for introduction of different molecules into the cell, electrofusion, 
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or water sterilization and food preservation. Among different theoretical 
models that describe electroporation, the transient aqueous pore model is most 
widely accepted. This model predicts hydrophilic pore formation as a response 
to induced external electric field on the cell membrane. Electroporation can be 
reversible or irreversible, depending on the electric pulse parameters used.  
 
Electroporation is affected on the one hand by parameters of electric pulses and 
chemical composition of the media used and on the other by the characteristics 
of the cell that is exposed to the electric field. The effect of the electric pulse 
parameters and electroporation media are briefly described. The most important 
electric pulse parameters are amplitude, duration, number, and repetition 
frequency. If those parameters exceed the optimal values, irreversible 
electroporation takes place due to cell membrane disintegration and DNA 
damage, resulting in cell lysis. The choice of electric pulse parameters thus 
depends on the desired application. Some applications require reversible, while 
others require irreversible electroporation. For loading of foreign molecules 
into the cell, reversible electroporation is required. The choice of electric pulse 
parameters depends on the type of the foreign molecule that is being 
introduced. For small molecules, such as different drugs or fluorescence dyes, a 
train of relatively short pulses (time duration in range of microseconds to 
milliseconds) is sufficient. For large molecules, such as DNA, longer pulses 
(range of few milliseconds) or a combination of high-voltage short-duration 
pulses and low-voltage long-duration pulses is used. Besides the before 
mentioned parameters of electric pulses, different pulse shapes can also be 
used. The most frequently used are exponential and square wave pulses. One 
should be careful when comparing results obtained by different pulse shapes, as 
the membrane polarization process that takes place during the pulse application 
is different. Electric pulses can be applied in one direction or their orientations 
can be changed during the pulse application. Such protocols were successfully 
used for 
electrochemotherapy and gene electrotransfer. 
  
 - 14 - 
 
For introduction of small molecules, short electric pulses in a range of tens to 
hundreds of microseconds are generally used. The most important parameter is 
pulse amplitude. It should reach a threshold value at which the electroporation 
of cell membrane is triggered. Above the threshold value the increase in 
electroporation is obtained with increase of pulse duration and number of 
pulses (Fig. 2). The increase in pulse duration increases the electroporation of 
cells until a plateau is reached and further increase in number of pulses or its 
duration does not affect cell electroporation. At the same time the increase in 
pulse number and pulse duration affects cell viability. The following 
explanation for the relationship between the pulse amplitude and the pulse 
number or duration was proposed: increasing the pulse amplitude results in 
larger area of membrane electroporation with smaller extent of electroporation, 
while increase in pulse number or duration does not affect the electroporated 
membrane area but increases the extent of electroporation (Fig. 3). 
 
Nevertheless, when increasing the duration of the pulse, one should also 
consider that longer pulses cause significant Joule heating of the sample. 
Systematic study of electric pulse parameters revealed that electroporation and 
cell viability are not related to the total electrical energy delivered. Further 
examinations of different parameters of electric pulses indicate complex 
dependence between electric pulse parameters and degree of electroporated cell 
membrane [20]. Another electric pulse parameter affecting electroporation of 
the cell membrane is pulse repetition frequency. When pulses are applied with 
high repetition frequency, above 1 kHz, the pause between two consecutive 
pulses is too short and does not allow cell membrane to return to pre-pulse 
state. From the experimental results it can be concluded that cell viability and 
cell membrane electroporation is optimal in the frequency range from 0.5 to 10 
Hz and decreases at higher frequencies. For reversibility of electroporation, the 
membrane potential has to be kept below the critical value. In such conditions, 
the cell membrane recovers after the electric pulse application. On the contrary, 
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when critical value is exceeded, irreversible electroporation takes place, 
resulting in cell membrane disintegration and loss of cell viability. 
 
The optimal conditions for introduction of macromolecules are different from 
optimal conditions for introduction of small molecules. Most experiments were 
performed with long, 5 to 10 ms pulses with relatively low pulse amplitude. 
When those results were compared with results obtained with higher voltage 
microsecond pulses, typically used for introduction of small molecules, it was 
established that many different pulse parameters are capable of delivering 
plasmid DNA into the cell. Protocols employing millisecond pulses are more 
efficient than microsecond pulses for long-term gene expression in vivo. The 
efficiency of gene electrotransfer into mammalian cells was first related to the 
pulse shape used, and exponentially decaying pulses were reported as more 
effective that the square wave pulses. Later, the use of combination of high-
voltage and low-voltage pulses was suggested. High-voltage pulse causes 
electroporation of cell membrane, while the low-voltage pulse helps highly 
charged DNA entrance into the cell interior. A low-voltage pulse thus provides 
electrophoretic movement of DNA into the cell in in vitro conditions, or it can 
be a powerful driving force for improving interstitial transport of DNA during 
gene delivery in vivo. The effect of electrophoretic pulses was successfully used 
and demonstrated in in vivo experiments in mammalian tissues [21]. 
Nevertheless, the role of electrophoretic force in DNA movement across 
permeabilized membrane is questioned for in vitro gene electrotransfer as no 
contribution of electrophoretic force could be detected. Lately the effect of 
electrophoretic movement of DNA by low-voltage pulse has also been 
questioned for in vivo applications [22]. The effect of low-voltage electric 
pulse on the highly charged DNA is alternatively attributed to electrophoretic 
accumulation of DNA on the cell membrane. It has also been demonstrated by 
visualization of DNA interaction with the cell membrane that the electric field 
orientation plays an important role in gene electrotransfer. Similar to small 
molecules, asymmetric DNA uptake is observed during electroporation. 
  
 - 16 - 
Nevertheless, DNA, unlike small molecules that enter cell cytoplasm on the 
membrane-facing cathode, enters the cell on the surface-facing anode. Another 
main difference between introduction of small molecules and DNA is that for 
successful gene electrotransfer, DNA has to be present in the medium before 
electric pulses are applied (Fig. 4) and the transport of the DNA through cell 
membrane takes place minutes after the pulse application. The complex 
between the DNA and the membrane forms only when the membrane is 
electroporated. If DNA is added after pulse application, no transfection can be 
observed. It was, however, demonstrated that transfection is successful if the 
DNA is added after the high-voltage pulse and before low-voltage pulse, but 
the level of DNA expression is lower. 
 
Single-cell electroporation is a suitable tool for the study of basic 
electroporation mechanisms. A few attempts were made to observe ultra-
structural changes related to electroporation; however, the process is too fast. 
Besides, chemical composition and fluid characteristics of the thin cell 
membrane make direct observation of primary membrane changes related to 
electroporation very difficult. The attempt was made to use rapid freezing 
scanning microscopy to determine the changes in membrane structure [14]; 
however, the size of the pores observed was 20 nm up to 120 nm, too large 
compared to theoretically estimated 1 nm, and the observed pores were most 
probably secondary structures. At the cell membrane level, the induced 
transmembrane potential was imaged by fluorescence probes sensitive to 
transmembrane potential changes induced by an external electric field. 
Temporal and spatial induction of transmembrane potential on the cell 
membrane that responds to externally applied electric field was observed with 
potentiometric dyes. The results obtained in those experiments on a single 
spherical cells are in good agreement with the theoretically calculated values 
obtained by Schwan’s equation. The value of induced trans membrane potential 
sustainable for living cell electroporation was determined to be 1 V. Later the 
value of the induced trans membrane potential that triggers electroporation was 
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determined to be in the range of 200–500 mV. These values obtained by 
fluorescence imaging and calculations were further confirmed by direct 
measurement at the single-cell level using patch clamp technique. 
 
The value of induced transmembrane voltage depends on the cell size, shape, 
and the position of the cell with respect to the direction of applied electric field. 
For a spheroidal cell, the maximum induced transmembrane potential strongly 
depends on its orientation with the respect to the electric field (Fig. 5). It is 
maximum when the spheroidal cell is parallel to the applied electric field. The 
distribution of induced transmembrane potential is asymmetric due to native 
transmembrane potential that is present in live cells. As the induced trans 
membrane potential caused by externally applied electric pulses is 
superimposed to the resting membrane potential of the cell, the side of the cell 
facing the anode is hyperpolarized while the side facing the cathode is 
depolarized The membrane labeling with fluorescent probes allows imaging of 
the membrane area affected by applied electric pulse. It was found that the 
membrane resting potential has a significant effect on asymmetric 
electroporation, especially when the induced trans membrane potential is close 
to the threshold voltage that triggers electroporation. This, however, is the case 
in majority of the applications in which cell viability needs to be preserved. The 
cell shape affects the site of cell membrane electroporation, and it is especially 
important in attached cells, as they are not at regular shape. The calculation of 
induced transmembrane potential on single cells, therefore, depends on the 
realistic cell shape that needs to be taken into account as it affects the 
calculated distribution of the induced transmembrane potential.  
Although a single-cell model is a valuable tool for the study of basic 
mechanisms of electropotaion, it is not the best method to predict 
electroporation behavior in a tissue. As a tissue is composed of cells that are 
close to each other, dense cell suspensions represent an intermediate level 
between the single-cell level and the tissue. Neighboring cells, even if they are 
not in direct contact, affect each other due to mutual electrical shading [23]. 
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For electroporation of cell suspensions, the proportion of the cells in the total 
volume is important. When they represent less than 1% of the volume fraction 
they behave as single cell, while for volume fraction greater than 10% or for 
clusters of cells, the induced transmembrane potential is affected by the 
suspension density. The fraction of electroporated cells decreases with increase 
in cell density and the resealing of cells in dense cell suspensions is slower. In 
dense cell suspensions, cell clusters, and multicellular spheroids it was found 
that the molecular tran sport is slower due to slower diffusion of molecules into 
the interior of such cluster or spheroid. Dense cell suspensions can serve as a 
model for tissues with homogeneous structure composed of similar cells in 
close contact; nevertheless, most tissues are not homogeneous. 
 
Tissues are composed of different cell types that are irregularly shaped, are 
vascularized, and present different electrical properties. All the mentioned 
factors affect the distribution of electric field within the tissue and consequently 
its electroporation efficiency [24]. Furthermore, cells in tissue are connected by 
gap junctions for intracellular communications and transport, which change the 
electroporation behavior of such cells, and they behave as a single larger cell.  
For efficient tissue electroporation in vivo, the electric field distribution, which 
depends on electrode geometry, position, and electrical properties of the 
sample, is crucial. The electrical properties of biological tissue such as 
conductivity and permitivity change once the tissue is permeabilized and the 
electric field distribution is changed. The largest part of these changes is 
attributed to increased membrane conductivity due to electroporation. Changes 
in membrane conductivity need to be taken into account when performing 
electroporation with multiple needle electrodes and can be used for detection of 
cell membrane electroporation and for pulse delivery control. Recently these 
changes were used for regulating the output voltage for in vivo gene 
transfection. One of the major problems with respect to conductivity 
measurements in vivo is the inhomogeneous distribution of current density and 
electric field due to inhomogeneous and anisotropic properties of the tissue. For 
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successful tissue electroporation, anatomically based mathematical models are 
important tools for prediction of the outcome of the treatment [24]. 
Single-cell electroporation is a suitable tool for study of basic electroporation 
mechanisms. The situation is more complex in tissues as they are composed of 
cells that are in close contact with each other and their proximity affect 
electroporation. Besides, most tissues are not homogenous structures, they are 
composed of different cell types that are irregularly shaped, are vascularized, 
and have different electrical properties that affect current density and electric 
field distribution, all of these affecting electroporation effectiveness. 
Mathematical models are thus a valuable tool for predicting electroporation 
behavior of the tissue. 
 
Pharmacological principles 
Because of their physico-chemical properties (e.g. charge, molecular weight, 
hydrophilicity) and/or their deficiency of membrane transport mechanisms, 
most anti-tumor drugs are poor or non-permeant molecules and their anti-tumor 
efectiveness is limited. Several chemotherapeutic drugs have been tested on 
cancer cell lines for potential application in combination with 
electropermeabilization. The main ECT mechanism is electropermeabilization 
of tumor cells, which enhances drug cytotoxicity by facilitating significant drug 
uptake to reach intracellular targets (e.g. nuclear DNA, phospholipids) (Fig. 6).  
Thus, cell electropermeabi-lization increases cytotoxicity of some 
chemotherapeutic drugs from approximately 1.1 up to several thousand-fold. 
Nevertheless, tp date only two of these drugs that are currently clinically used 
in combination or not with other drugs have been recognized as potential 
candidates for ECT of cancers in clinical human and veterinari treatments: 
cisplatin (CDDP) and bleomycin (BLM). Cisplatin transport through the 
plasma membrane is also limited. 50% of cisplatin is conveyed through the 
plasma membrane by passive diffusion and the remainder is transported by 
receptors. Cisplatin has been most extensively characterized as a nuclear DNA 
damaging agent and the cytotoxicity of cisplatin has generally attributed to the 
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ability to form inter- and intra-strand DNA crosslinks (Fig. 7). This mechanism 
is believed to be the main cause of the anti-proliferative effect of cisplatin. In 
fact, only approximately 1% of intracellular platinum is bound to nuclear DNA. 
The great majority of the intracellular drug is available to interact with other 
nucleophilic sites on other molecules. Thus, cisplatin binds to mitochondrial 
DNA, induces endoplasmic stress, interacts with phospholipids and 
phosphatidylserine in membranes, disrupts the cytoskeleton and affects the 
polymerization of actin. Membrane electropermeabilization enables increased 
cellular flux and accumulation of the drug, which results in an enhancement of 
cisplatin cytotoxicity by up to 80-fold. The transport of bleomycin across the 
plasma membrane is achieved by receptors that internalize it via the 
endocytosis process. The low number of receptors exposed at the cell surface 
limits this process. Thus, this pathway limits the uptake of bleomycin and its 
cytotoxicity. The controlled exposure of cancer cells to electric pulses leads to 
increased membrane permeability and enables the direct access of bleomycin to 
the cell's cytoplasm. Bleomycin acts by inducing DNA strand breaks by an 
oxygen- and metal ion-dependent process. Indeed, bleomycin chelates metal 
ions, producing a pseudo-enzyme that reacts with oxygen to produce 
superoxide and hydroxide free radicals that cleave nuclear DNA. Moreover, 
these complexes also mediate lipid peroxidation and oxidation of other 
endogenous molecules such as proteins (Fig. 8). A few hundred molecules are 
only required for the cytotoxicity. Previous investigations showed that 
electropermeabilization of cancer cells potentiates the cytotoxicity of 
bleomycin up to several thousand-fold [25]. 
 
Antitumor action 
Besides membrane permeabilization, Sersa and colleagues showed that the 
application of electric pulses to targeted tissues induces a transient, reversible 
and profound reduction of tumor blood flow (i.e. 80% decrease) [26−27]. This 
phenomenon, called vascular lock, allows drug entrapment in the targeted 
tissue up to several hours providing more time for the drug to act. The time 
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course of blood flow changes has been described. It follows the same two-
phase pattern. The first rapid and short-lived vasoconstriction phase is followed 
by a much longer-lived second phase resulting from disrupted cytoskeletal 
structures and a compromised barrier function of microvascular endothelium 
causing endothelial 
cell permeabilization and drug extravasation enhancement. The uptake of 
chemotherapeutic drugs into tumor vascular endothelial cells leads to 
unrepairable damages to tumor vessels and to a further decrease in tumor blood 
flow within hours after electrical treatment. Consequently, the ECT potentiates 
the destruction of tumor vasculature and breaks down the nutrient supply (e.g. 
oxygen, growth factors), which induces the cell death of tumor cells. In all this 
is the direct effect of ECT. Vascular disrupting contributes to the increase of 
antitumor effectiveness of bleomycin and cisplatin. Indeed, the anti-vascular 
effects of ECT are also exploited for palliative treatment of bleeding melanoma 
metastases, with immediate stop of bleeding and very good anti-tumor 
effectiveness. This anti-vascular effect could play a major role into the 
treatment of deep-seated vascular tumors. 
 
In the 90s, Mir and colleagues first showed that the host immune response is 
essential for obtaining cures after ECT [28]. The tumor growth delay in 
immunocompetent mice was approximately twice than in immunodeficient 
mice. Thus, 80% of tumors cures were achieved in immunocompetent mice but 
none in immunodeficient mice [44]. On the basis of experimental fact, systemic 
ECTinduced immunity can be upregulated by additional treatment with 
immune-boosting molecules such as interleukin-2 and -12, and TNF-α. The 
antitumor effectiveness of such combinations was tested in different types of 
primary tumors, distantly growing tumors and induced metastases. Indeed, 
intratumoral IL-12 electrogene therapy has been proved to be very effective in 
local tumor control, having also a systemic effect. Moreover, intramuscular and 
peritumoral IL-12 electrogene therapy had also a pronounced systemic effect 
and when combined with other treatment (e.g. electrochemotherapy) resulted in 
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tumor cures [29]. The anti-tumor effectiveness of such molecules is due to the 
induction of adaptive immunity and innate resistance and anti-angiogenic 
action. 
 
 
Equipment 
Electroporation is used for different purposes and depending on the application 
one should chose the right electrodes to obtain the desired result. For different 
applications, different types of electrodes are available and can be classified 
according to their geometry into different groups: plate, needle, wire, and 
tweezers electrodes [30]. In certain cases, special electrodes are needed; for 
example, for individual-cell electroporation, specially designed microelectrodes 
are required. For treatment of large volumes of sample and for flow 
electroporation, electroporation chambers that allow efficient treatment were 
designed and successfully tested. They were successfully used for gene 
transfection or water treatment. The choice of most suitable electrodes for a 
given application depends also on the characteristics of the treated sample. 
For reversible electroporation used in medicine, electrode design have to allow 
efficient electroporation and at the same time cause as little cell damage of the 
surrounding tissue as possible. In in vivo electroporation, electrical properties 
of the treated tissue have to be taken into account, as they vary significantly 
among different tissues. In electroporation, mathematical models taking into 
account the tissue conductivity changes can be very useful for proper electrode 
selection and their positioning with respect to the tissue that needs to be 
electroporated, since the electric field distribution can be efficiently modified 
by electrode geometry and their position during the pulse application. 
Irreversible electroporation, used in water sterilization and food preservation, 
where large volumes need to be treated and high electric fields need to be 
applied, requires different methodologies. For flow electroporation, it is crucial 
that the pulse delivery frequency is linked to the flow rate in such a way that 
each cell that passes electroporation chamber receives electric pulse treatment. 
  
 - 23 - 
Liquid flow during electroporation affects causes cell elongation therefore 
electric field orientation with respect to cell is important. The choice of proper 
electrode shape and their position during the pulse application is crucial for 
successful treatment, as they affect the electric field distribution. The most 
appropriate electrode type and positioning depends on the application. 
 
Pros and cons of ECT treatment 
Although highly effective, up to now ECT has been limited to the treatment of 
superficial (cutaneous and subcutaneous) or low deep tumors (indicatively, 3 
cm). Consequently, further developments are focusing on the treatment of 
internal tumors by the development of flexible electrodes, endoluminal 
electrodes, long needle electrodes and small-size electrodes. 
 
Electrochemotherapy is currently used for the treatment of cutaneous and 
subcutaneous tumour nodules of any type of malignancies. The advantages for 
electrochemotherapy can be summarised as follows. 
First, the effectiveness in tumour nodules of different histologies. Melanoma 
was the predominant tumour type in the first clinical trials, however, there are 
several reports demonstrating effectiveness of ECT on other types of recurrent 
tumours or metastases, like breast carcinoma, head and neck tumours, 
squamous cell carcinoma, basal cell carcinoma and others in more sporadic 
reports. The objective response rate of non-melanoma tumours was the same as 
of melanoma tumours 81%, which indicates on equal effectiveness of ECT on 
different tumour types. The rationale for the obtained results is simple, either 
bleomycin or cisplatin, when reaching intracellular targets, exert their cytotoxic 
action, if sufficient amount of the drug is present in the cells. Since electric 
pulses induce electropermeabilisation of the cells, in electrochemotherapy more 
drug is able to reach its intracellular targets, 
the cell DNA, which explains the higher efficacy of these drugs in association 
with application of electric pulses to the tumours. 
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Second, the minimal side effects. Electrochemotherapy is easy and quick (i.e., 
25 min) to perform, in majority of cases on out-patient basis (as clearly stated 
in the SOP). Therefore, it has minimal burden to the patients, since in most case 
its effectiveness was demonstrated after a single treatment. However, it could 
be repeated with equal antitumour effectiveness, if the tumour nodules recur or 
if new tumour nodules emerge. After treatment no specific care or dressing of 
the treated nodules is required. All these aspects, and the fact that 
electrochemotherapy can be performer also in patients with contraindications 
for surgical treatment or radiation therapy and in elderly patients, provide 
evidence that electrochemotherapy has substantial impact on quality of life in 
cancer patients with progressive disease. Furthermore, electrochemotherapy is 
performer with low doses of bleomycin or cisplatin therefore no sistemi side 
effects were observed.  
Third, ECT iso f simple application. It be performed in general or local 
anaesthesia. In either of the procedures it is a simple procedure that can be, in 
the case of local anaesthesia, performer on an out patient basis. No extra 
technical skills are needed to perform the treatment, an 1 day training session is 
sufficient to perform the treatment according to the prepared SOP. Therefore, it 
is a procedure that can be performed also in developing countries and small 
hospitals, where other standard treatments are not readily available. In 
comparison with the complexity of other local or regional treatments like 
radiotherapy, isolated extremity perfusion and infusion it is much more simple. 
Fouth, the possibilità of repetitive treatments. Electrochemotherapy is an 
effective treatment when sufficient drug concentration is obtained in the tumour 
nodules and the whole tumour volume is adequately covered by application of 
electric pulses, so that most of the tumour cells are electroporated. In the case 
of bigger tumour nodules that are not covered by electric field in single run of 
electric pulse application, several applications of electric pulses are required. In 
such cases viable tumour cells may remain, therefore recurrent or remaining 
tumour mass must be retreated. Electrochemotherapy is very effective in 
repetitive treatments as demonstrated in several clinical cases. The treatment 
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can be repeated in 3–6 weeks interval with the same treat-ment effectiveness as 
in the previous treatment.  
Finally, the effectiveness in tumours emerging in pre-treated areas. ECT was so 
far tested in patients with progressive disease, where other standard treatment 
procedures have failed or were exhausted. In some cases the recurrent tumour 
nodules were in previously irradiated areas or in the area of the surgical field of 
the previously removed nodules. Clinical data demonstrated effectiveness in 
most of these cases, regardless of being in previously irradiated areas or in 
previously resected areas, or in the skin flap. In such cases standard 
interventions are no longer possible and electrochemotherapy provides 
treatment of choice for these tumours. 
 
Indications to ECT 
In medicine, electroporation is used in ECT in clinical practice for improved 
drug delivery for cancer treatment, and in preclinical trails for gene 
electrotransfer. From the point of view of medical applications, it is more 
convenient to use a high-repetition pulse frequency rather than 1 Hz pulse 
repetition, which is currently used in clinical trials. This is important when 
larger tumor nodules need to be treated and when multiple needle electrodes are 
used. In that case, a large number of pulses need to be delivered to each of the 
pairs of the electrodes, which would represent an unpleasant and a relatively 
long treatment time, if pulses were delivered at 1 Hz repetition frequency. The 
application of pulses with higher repetition frequency does not significantly 
affect the electrochemotherapy efficiency and the treatment is less unpleasant 
than application of pulses with standard 1 Hz repetition frequency. At the in 
vivo level, tissue vascular lock is observed due to disruption of blood vessel 
network after the application of high-voltage pulses. Consequently, the tissue 
oxygenation level is reduced by electroporation resulting in enhanced tumor 
cell death. 
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CLINICAL ELECTROPORATION: THERAPEUTIC APPROACHES 
 
Electro-gene-deliery (EGT) 
The goal of any gene transfer method is to deliver genes to desired cells in 
tissues and organs in an efficient manner with minimal toxicity. The main 
problem associated with nonviral gene transfer has been modest transgene 
expression secondary to inefficient in vivo transfection. Electroporation 
provides a means for transporting polynucleotides directly across the cell 
membrane into cells (Fig. 9). This process appears to enable the cytoplasmic 
entry of more of the delivered molecole compared to other nonviral methods. In 
addition, the electrophoretic effect may also facilitate intracellular transport to 
the nucleus once cytoplasmic uptake has occorre [31]. Extensive mechanistic 
research, mathematical modeling, and empiric development has been 
completed, and these studies provide significant insights into the basic 
mechanism of this procedure. Rational manipulations of electroporative 
parameters geared toward specific tissue features and laboratory conditions are 
possible. This gene delivery method relies on biophysical parameters rather 
than receptor expression, and therefore optimized methods appear to be easily 
transferred to enable transfection of similar cell types in different species. As a 
consequence, the successful use of electroporative nonviral gene transfer is 
rapidly becoming clinically feasible for a wide range of gene correction, gene 
therapy, and nucleic acid vaccine applications [32]. Furthermore, simple and 
efficient nonviral gene transfer methods like in vivo electroporation may also 
enable new opportunities for functional genomics research via direct somatic 
tissue transfection. To realize such oppor tunities, future research must address 
and overcome the mechanisms of toxicity, define the interaction between 
electroporative conditions and nucleic acid structure and size, and identify 
transcriptional elements that may be used to control the levels and distribution 
of transgene expression.  
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Irreversibile electroporation (IRE) 
Irreversible electroporation (IRE) is in some applications the undesired, while 
in others it is the desired outcome of the electric pulse application. It is a 
consequence of membrane rupture that is a directly caused by electric pulse 
application. IRE and Joule heating are an integral part of electrical injury, 
which affects especially nerve and muscle cells due to their size. Release of 
intracellular components from affected cells cause acute renal failure due to 
deposition of iron-containing molecules such as mioglobin. Successful 
treatment of electroporated membranes with nontoxic polymers can reduce 
tissue injury produced by irreversible electroporation due to sealing of 
electroporated cell membranes. IRE is the desired result when it is used for 
microbial deactivation in water and food treatment. The applied electric pulses 
should cause irreversible damage of treated cells. For effective treatment, 
critical electric field parameters should be chosen properly. Typical pulse 
amplitude for microbial deactivation in water and liquid food is between 20 and 
35 kV/cm, pulse duration, from micro- to milliseconds, and pulse number 
varies from ten to hundred pulses. For food preservation, amplitudes used are 
lower than for microbial inactivation in freshwater and liquid food. The main 
problem is the choice of optimal treatment parameters that would require 
minimal power consumption and would effectively disintegrate treated cells. 
Recently, irreversible electroporation was reported as an alternative minimally 
invasive surgical technique in medicine for tissue ablation of breast and 
pancreatic cancer [33-36]. For in vivo applications, mathematical models 
provided a valuable tool for proper electrode positioning and optimal pulse 
parameter determination for effective treatment [34]. 
 
Nanoelectroporation (nEP) 
Typically, 1300 V/cm, 100 ls pulses were used for skin cancer trials. Most 
studies have used six or eight pulses with an interval of 1 s (1 Hz). For gene 
therapy, lower intensity and longer pulses, such as 125 V/cm, 25 ms; 200 V/cm, 
10 ms have been found to be effective. Lately, ultra-short pulses of nanosecond 
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(ns) durations and 10–300 kV/cm (nsEP) have been used for electroporation. 
Under these conditions, the plasma membrane acts as a short circuit allowing 
the pulse to directly manipulate the internal organelles of the cell. Hallmarks of 
apoptosis, including phosphatidylserine translocation, and caspase activation 
have been observed with high-intensity nanopulse electroporation. With these 
effects, it is expected that the use of ultra-short pulses of sub-microsecond or 
nanosecond durations could be used for additional applications in 
biotechnology and medicine, specifically for cancer/gene therapy. The use of 
high-intensity DC pulses with durations shorter than the time constant of 
membrane charging (1 ls) can offer valuable insight into the biophysical 
mechanisms involved in the electropermeabilization of the cells [37]. However, 
due to the complexity of the design and the high cost involved in constructing a 
nanoelectroporation system, there is no commercially available nanopulsers. 
 
ECT: EVOLUTION OF CLINICAL APPLICATIONS 
 
First clinical trials 
An overview of the clinical data on electrochemotherapy is provided in Tables 
1 and 2 [38].  
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The first report on the use of electrochemotherapy in treatment of cancer 
patients was by Mir et al. from Institute Gustave Roussy, Villejuif, France in 
1991 and 1993. This phase I/II study was launched after preclinical studies 
demonstrating good antitumour effectiveness of bleomycin given intravenously 
and subsequent electroporation of the tumours, which is discussed in this issue 
in the article of L.M. Mir. In the clinical study 8 cancer patients with 40 head 
and neck squamous carcinoma nodules were treated. Objective responses were 
obtained in 72% and among these complete responses were obtained in 57% of 
the treated nodules. The tumour nodules that were treated with bleomycin only 
did not respond to the treatment. No side effects were reported, and even 
ripetitive treatment proved to be successful. This first clinical study 
demonstrated feasibility and also effectiveness of electrochemotherapy, as well 
as it indicated that electrochemotherapy may be effective also on tumours of 
different histological origin, due to the theoretical basis of electroporation 
principle for drug delivery. This was proved by other groups from Toulouse, 
France, Tampa, USA, and Ljubljana, Slovenia, which launched their own 
clinical trials on electrochemotherapy with bleomycin given intravenously on 
different tumour types, namely melanoma, basal cell carcinoma, and 
adenocarcinoma. New approach in electrochemotherapy, the use of bleomycin 
given intratumourally was introduced in 1996 by Heller’s group from Tampa, 
USA.17 That study involved 5 patients with 23 melanoma metastases that were 
treated by electrochemotherapy with bleomycin given intratumourally. Very 
good antitumour effectiveness was observed. Objective response rate was 95%, 
with 78% of complete responses.  
Altogether, these first studies using electrochemotherapy with bleomycin given 
either intravenously or intratumourally demonstrated that this treatment 
approach is effective on cutaneous tumour nodules of different histology with 
good local tumour control. Results of all clinical trials performed in five cancer 
centres that have been involved in electrochemotherapy, were summarised in 
1998 by Mir et al. The results were gathered from Institute Gustave Roussy, 
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Villejuif, France, University of South Forida, Tampa, USA, Institute of 
Oncology, Ljubljana, Slovenia, Centre Claudius-Re´gaud, Toulouse, France 
and Institut Jean-Godinot, Reims, France. Clinical experience on 
electrochemotherapy with bleomycin given either intravenously or 
intratumourally on 291 cutaneous or subcutaneous tumour nodules in 50 cancer 
patients was reported. Electrochemotherapy was performed on tumour nodules 
originating from basal cell carcinoma, melanoma , adenocarcinoma, and head 
and neck squamous cell carcinoma. Objective responses were obtained in 233 
(85%) of the 273 evaluable tumour nodules that were treated with 
electrochemotherapy, from these 154 (56%) tumour nodules were in complete 
response. This study clearly demonstrated that electrochemotherapy with 
bleomycin is effective in treatment of tumour nodules with different histology, 
and that the results of the treatment were comparable between the five cancer 
centres, in spite of small differences in treatment protocols that they used. 
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The next milestone was the introduction of cisplatin, a widely used 
chemotherapeutic drug, into electrochemotherapy protocol. The first reports on 
electrochemotherapy with cisplatin were by Sersa et al. from Institute of 
Oncology Ljubljana, in 1998. In separate publications the results on antitumour 
effectiveness of electrochemotherapy with cisplatin given intravenously or 
intratumourally on melanoma, basal cell, squamous cell and adeno carcinoma 
tumour nodules were presented. In the first study, application of electric pulses 
was performed on accessible melanoma tumour nodules in patients that were 
receiving standard intravenous cisplatin-based chemotherapy regimen. 
The antitumour effectiveness of electrochemotherapy, i.e. application of 
electric pulses to tumour nodules together with cisplatin-based therapy was 
compared to the antitumour effectiveness of cisplatin-based therapy given 
intravenously alone. In 9 malignant melanoma patients, electrochemotherapy 
resulted in 48% objective responses of 27 treated nodules, whereas in 18 
tumour nodules treated with cisplatin-based therapy 22% objective response 
rate of the tumour nodules was obtained. Furthermore, the median time to 
progression was longer in electrochemotherapy treated nodules (21 weeks) than 
in the cisplatin-based therapy treated nodules (4 weeks). It has to be 
emphasised that the treated tumour nodules in that study were much bigger than 
those treated in studies using bleomycin; therefore, it could be expected that the 
response rate was lower. However, no further attempt to introduce 
electrochemotherapy using cisplatin given intravenously was made, based on 
the good results obtained using electrochemotherapy with bleomycin, given 
intravenously and electrochemotherapy with cisplatin, given intratumourally. 
The second study presented the results on electrochemotherapy with cisplatin 
given intratumourally in melanoma patients. The group from the Institute of 
Oncology Ljubljana reported results on 133 tumour nodules in 10 melanoma 
patients. Eighty-two tumour nodules were treated with electrochemotherapy 
using cisplatin given intratumourally, 27 tumour nodules were treated with 
cisplatin intratumourally, 2 tumour nodules were treated with electric pulses 
alone and 22 tumour nodules were untreated. The untreated nodules and the 
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nodules that were treated with electric pulses alone were subsequently treated 
with electrochemotherapy. A significant potentiation of antitumour 
effectiveness of cisplatin was demonstrated in electrochemotherapy treated 
nodules, whereas exposure of tumour nodules to electric pulses without 
cisplatin had no effect on tumour growth. Four weeks after therapy 78% 
objective responses were obtained in the electrochemotherapy group with 68% 
complete responses, and 38% objective responses were obtained in cisplatin 
group with 19% complete responses. At 124 weeks of follow up, a 77% control 
rate of tumour nodules treated by electrochemotherapy was observed, compared 
to 19% of those that were treated with cisplatin only. These data were 
confirmed by successive study on 14 melanoma patients where 211 tumour 
nodules were treated by electrochemotherapy with cisplatin given 
intratumourally. Objective response rate was 81%, with 70% of complete 
responses of the electrochemotherapy treated nodules. Based on these studies 
cisplatin was recognised as one of the two drugs that can be used in 
electrochemotherapy with intratumoural drug injection).  
 
The presented studies form the basis for implementation of 
electrochemotherapy showing that electrochemotherapy can be used in tumours 
of different histological origin and that those two drugs, namely bleomycin and 
cisplatin can be successfully employed in combination with electroporation. It 
was also shown that bleomycin can be administered either intravenously or 
intratumourally while for the cisplatin, intratumoural administration results in 
better response compared to intravenous administration.  
 
ESOPE study 
This multi center study had thepurpose to evaluate and confirm efficacy and 
safety of electrochemotherapy with bleomycin or cisplatin on cutaneous and 
subcutaneous tumour nodules of patients with malignant melanoma and other 
malignancies [39]. This was a two year long prospective non-randomised study 
on 41 patients evaluable for response and 61 evaluable for toxicity. Four cancer 
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centers enrolled patients with progressive cutaneous and subcutaneous 
metastases of any histologically proven cancer. The skin lesions were treated by 
electrochemotherapy, using application of electric pulses to the tumours for 
increased bleomycin or cisplatin delivery into tumour cells. The treatment was 
performed using intravenous or intratumoural drug injection, followed by 
application of electric pulses generated by a CliniporatorTM using plate or 
needle electrodes. Tumour response to electrochemotherapy as well as possible 
sideeffects with respect to the treatment approach, tumour histology and 
location of the tumour nodules and electrode type were evaluated. 
An objective response rate of 85% (73.7% complete response rate) was 
achieved on the electrochemotherapy treated tumour nodules, regardless of 
tumour histology, and drug used or route of its administration (Fig. 10). At 150 
days after the treatment (median follow up was 133 days and range 60–380 
days) local tumour control rate for electrochemotherapy was 88% with 
bleomycin given intravenously, 73% with bleomycin given intratumourally and 
75% with cisplatin given intratumourally, demonstrating that all three 
approaches were similarly effective in local tumour treatment (Fig.11). 
Furthermore, electrochemotherapy was equally effective regardless of the 
tumour type and size of the nodules treated. Side-effects of 
electrochemotherapy were minor and acceptable, as reported by the patients. 
Conclusion:We demonstrated that electrochemotherapy is an easy, highly 
effective, safe and cost-effective approach for the treatment of cutaneous and 
subcutaneous tumour nodules of different malignancies. Electrochemotherapy 
can provide immediate clinical benefit in patients with advanced cutaneous and 
subcutaneous metastases. 
 
European Standard Operating Procedures of ECT 
The aim of this document was to define the standard operating procedures 
(SOP) in order to safely and conveniently treat, by electrochemotherapy, 
patients with cutaneous and subcutaneousnodules. This document provides the 
reader with the basis for understanding the mechanisms of the 
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electrochemotherapy aswell as its possibilities as antitumour treatment. It also 
has a decision chart to help the physician in choosing among the different 
treatment modalities reported in this SOP [40]. 
 
The Italian Experience 
ECT has been introduced in Italy in 2005. So far only a few centers have been 
able to collect an adequate case load in order to evaluate the clinical impact of 
the procedure. Nowadays many centres are equipped with the Cliniporator 
pulse generator in Italy and are ready to start treating patients with ECT. We 
here report the clinical experience on the use of ECT gained so far in Italy, at 
the Torino and Padova University. Actually, up to now this new treatment 
approach has been applied mainly in patients with superficial metastases from 
different tumor types unsuitable for conventional treatments. 
Authors from the Dermatologic Clinic of the University of Torino published a 
prospective nonrandomized study on 14 melanoma patients [41]. An objective 
response was obtained in 153/160 (95%) lesions, with a CR rate of 62%. No 
differences in response rate were observed between cutaneous and 
subcutaneous metastases. The lesion size was the most predictive parameter for 
response. Indeed, a response was obtained in 123/124 (99%) metastases sized 
≤1 cm2 and in 30/36 (83%) larger lesions. 
Another large, retrospective series was published by our group in 2009 [42]. 
The main aim of this study, which was the largest ever reported so far, was to 
evaluate not only the toxicity and the activity of bleomycin-based ECT 
performed according to ESOPE but also the response duration and the impact 
of ECT on disease-related symptoms and patients’ functioning in everyday life 
by means of a dedicated questionnaire. It’s crucial to assess whether this 
treatment is useful to improve quality of life, given that ECT application is 
mainly accepted, by the oncological community, in the palliative setting.  
Antitumor activity was observed in all tumour types and both in melanoma and 
non-melanoma metastases (CR was obtained in 17/34 melanoma patients and 
in 9/18 non-melanoma patients). One month after the first ECT application, 125 
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out of 267 (47%) target lesions showed CR, 126 (47%)  PR and 16 (6%) NC. 
As regards the factors influencing tumor response, it was observed an inverse 
correlation between complete local response and the maximum diameter of the 
target lesion: 66% for tumours <1,5 cm, 36% for nodules between 1,6 cm and 3 
cm and  28 % for those > 3 cm. Tumor response does not appear to be affected 
by the  drug administration route, as similar response rates were observed in 
patients who underwent ECT with intralesional, intravenous and combined 
bleomycin injection.    
One month after the first ECT application an objective response was obtained 
in 50 of 52 patients (96%): in particular, according to RECIST criteria there 
were 26 complete (50%), 24 partial (46%) responses. In two patients (4%) there 
was no change in tumor size. Among 26 complete responders at the first ECT, 
17 are locally disease free after a median follow-up of 9 months (range: 2-21 
months). 
The questionnaire for evaluation of patients’ perception was completed in 36 
cases (69%). The local disease-related complaints, if present, were the 
following: difficulty in sitting (as a consequence of treatment of large tumors 
on the back, n=4); walking (due to a tumor nodule on the foot, n=2); bathing 
(due to ulcerated disease, n=2); dressing (because of oozing, n=7); mastication 
(tumor nodule on the oral mucosa, n=1); pain (n=22). Thirty-four of 36 patients 
(94%) declared a positive impact of ECT on one or more of the items 
investigated before and after treatment (wound healing, bleeding, aesthetic 
impairment, activity of daily living, social relation, pain control). Nearly all 
patients (93%) experienced a local benefit, as demonstrated by the 
improvement of the scores assessing ulceration and bleeding, with a better 
aesthetics appearance stated by 31 of 36 patients. Among these patients, five 
with tumor nodules on the head and neck region indicated an improvement in 
aesthetic appearance at 1- and 2-months survey. Nine patients indicated an 
improvement in some of the activities of daily living as a consequence of 
tumour treatment and six in social relations. A better pain control was 
registered in 9 out of 22 patients with painful tumor nodules. Overall, 34 of 36 
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patients were satisfied of the treatment received, 1 uncertain, 1 unsatisfied; 34 
of 36 (94%) patients were keen to further ECT in case of recurrence. The sum 
of the scores obtained in the six items (bleeding, ulceration, aesthetics, pain, 
activity of daily living, social relation) registered after ECT (at 1 month and 2 
months) were statistically different as compared to that registered before 
treatment.  
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STUDY AIMS 
 
 
The principal milestones of this study were the following: 
 
- the evaluation of ECT antitumor activity, together with its toxicity and    
effectiveness in local tumor control, in different subgroup of cancer patients 
(melanoma, sarcoma, breast cancer, head and neck cancer) 
 
- the introduction and implementation of a new pulse generator and new 
needle electrodes for ECT treatment to large and deep soft-tissue tumors 
 
- the individuation of possible advancements to improve ECT delivery (in 
order to obtain a more precise electric field application to the tumor) or 
effectiveness biologists (in order to sensitize cancer cells to bleomycin or 
stimulate a systemic immune system reaction with ECT-induced tumor necrosis    
 
- the study of TLRs levels of expression in tumor samples before and 
following ECT application to melanoma cancer patients 
 
- the investigation of the sensitizing effect to BLM of L-Buthionine 
sulfoximine (BSO), a specific γ-glutamylcysteine synthetase inhibitor that 
blocks the synthesis of glutathione (GSH)  
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METHODS 
 
PROJECT’S OVERVIEW 
 
An overview of the milestones of this project id provided in Fig. 12. Four 
phase-II studies have been designed to evaluate ECT in the clinic: three of them 
have bee carried out and completed at the Veneto Region Oncology Research 
Institute of Padova to determine the activity and safety of ECT in melanoma 
(n=85), breast cancer (n=35) and sarcoma patients (n=34, in collaboration with 
the Rizzoli Orthpaedic Institute of Bologna). The fourth prospective study, 
focusing on ECT application to large and deep tumor, is still open and enrolling 
patients (currently, accrual has reached 20 of 35 patients). An additional 
retrospective study was performed, iun collaboration with the Institute of 
Oncology of Ljubliana, Slovenia,  in 42 patients with head and neck cancer. 
Gene expression analysis of TLRs in metastatic melanoma patients who 
underwent BLM-ECT treatment was performer in collaboration with the 
Surgery Branch of the Oncological and Surgical Sciences of the University of 
Padova. 
In vitro cytotoxicity tests on melanoma cell lines (B16-F10 and SK-MEL-28) 
were performer through the WST-1 proliferation assay,  in collaboration with 
the University of Ferrara, Department of Morphology and Histology.   
 
PATIENTS’ INCLUSION CRITERIA 
 
In general, the patients enrolled in the clinical trials had superficial tumor 
nodules (not deeper than 3 cm), except for the study on deep-seated soft tissue 
tumors, in which the enrolled patients had tumor of 3-6 cm size and maximum 
20 cm depth. Incluson criteria for each study are detailed in the respective 
paragraph within the Results section.   
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TUMOR REGISTRATION 
 
Tumor nodules were registerd and theit largest diameter recorded, in 
accordance with RECIST (Response Evaluation Criteria in Solid Tumors) 
Criteria. 
 
PATIENT MANAGEMENT 
 
The anaeshesiologic management was choosen according to the anatomical site 
to be electroporated, disease extension and patient comorbidity and ranged 
from a local anaesthesia to a genral anaesthesia, passing through a general 
pharmacological sedation with Propofol, Fentany and Ketamine.  
 
TREATMENT 
 
Anesthesia 
Local anestesia. A rectangular infiltration of local anaesthetic (Lidocaine, 2%, 
with epinephrine 0.5%) around the area to be treated, by injecting along 4 lines 
so that the nodule is ‘fenced in’ by local anaesthetic. If more than one nodule is 
to be treated, it is necessary to consider the total amount of lidocaine: for 
example, in a 70 kg patient the maximal dose without adrenaline is 210 mg (21 
ml of 1% lidocaine or 10.5 ml of 2% lidocaine) and with adrenaline 420 mg (42 
ml of 1% or 21 ml of 2%). This will set the maximum of nodules treatable by 
one session with local anaesthesia, not surpassing 3 mg/kg of lidocaine without 
adrenaline or 6mg/kg for lidocaine with adrenaline. If it is anticipated that there 
will be less than 0.5 cm from the tip of the electrodes to periost, local 
anaesthesia should be reconsidered, since it may be difficult to palliate the 
patient sufficiently. Another potential restriction to local anaesthesia is the 
localization of the nodules in previously irradiated areas: experience has shown 
that is seems more 
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difficult to apply local anaesthesia in these previously irradiated areas and if the 
option ‘‘local anaesthesia’’ is confirmed, it is recommended to put more 
anaesthetic and allow more time for lidocaine diffusion. Small cutaneous 
tumours may be anaesthetized by local infiltration of lidocaine just below the 
tumour, however, still covering the area of electroporation. This may increase 
the number of small nodules that can be treated with local anaesthetic in one 
session. Premedication with sedatives does not seem necessary. 
 
Analgo-sedation. Analgesia is started at least 3 min before intratumoural 
injection: remifentanil 0.5 lg/kg bolus then 0.1–0.15 lg/kg/ min then adjusted to 
the response to the first pulses or target controlled infusion (target 2 to 4 
ng/ml). It may also be replaced by alfentanil boluses 250–750 µg. Sedation is 
then started: propofol 0.5 mg/kg then 2–4 mg/ kg/h or target controlled infusion 
(target 1 to 2 lg/ml). Both are stopped at the last pulse. Post-operative pain is 
usually very low to moderate. Post-operative analgesia can be provided by 
intravenous paracetamol (1 g) and tramadol (100 mg), or paracetamol per 
rectum, as soon as the ECT started. It may be renewed every 6 hours until the 
24th hour. Alternatively, instead of giving the paracetamol in a prophylactic 
way, it can be just offered to the patient after the procedure. No systematic 
prevention of nausea and vomiting is given but nausea or vomiting episodes 
can occur in a few sensitive patients. They spontaneously resume.  
 
Drugs 
Cisplatin 
Intratumoural injection: 
– dissolve to 2 mg/ml with sterile water 
– protect from direct light 
Injected dose is 0.25 ml (0.5 mg) per cm3 of tumour tissue for tumours larger 
than 1 cm3, and 0.5 ml (1 mg) per cm3 of tumour tissue for tumours smaller 
than 1 cm3 but larger than 0.5 cm3. For tumours smaller than 0.5 cm3 injected 
  
 - 41 - 
dose should be 1ml (2 mg) per cm3, as a somewhat larger loss to surrounding 
tissues would be anticipated (see Table 3 below). 
 
 
Table 3. Intratumoral cisplatin dosages according to tumor volume 
 
Bleomycin 
Intratumoural injection: 
Bleomycin distributed in vials each containing 15000 IU of bleomycin, 
determined by its activity. Previously, the term units has been used, where 
15000 IU = 15 units. The recommended concentration of injection solution is 
1000 IU/ml, dissolve in sterile water. • Injected dose should be 0.25 ml (250 
IU) per cm3 of tumour tissue for tumours larger than 1 cm3, and 0.5 ml (500 
IU) per 
cm3 of tumour tissue for tumours smaller than 1 cm3 but larger than 0.5 cm3. 
For tumours smaller than 0.5 cm3 injected dose should be 1 ml (1000 IU) per 
cm3 (Table 4). 
 
Table 4. Intratumoral BLM dosages according to tumor volume 
 
Intravenous injection: 
The doses of bleomycin are low and there is not amandatory need for 
premedication. Bleomycin is infused at 15,000 IU/m2. The bolus lasts not less 
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than 30 s but in not more than 1 min. After 8 min from BL infusion, allowing 
the drug to diffuse into tissues, electric voltages are administrated. 
 
Electrodes 
The appropriate electrode was choosen according to the tumor characteristics. If 
the tumour is less than 1 cm, consider using either plate or parallel array 
electrodes. In case the tumour is more than 1 cm, consider using the hexagonal 
array electrodes. Plates or needles depending on the location of the small 
nodule, respectively superficial or more deeply located (Fig. 13-14). Treating at 
a frequency of 5 kHz will reduce the number of contractions to one – however 
this contraction will be more forceful than if a frequency of 1 Hz is used. The 
use of the 5 kHz frequency is mandatory for the electrodes of type III 
(hexagonal geometry). 
 
Post-treatment management 
The patients are followe-up 4 weeks post-treatment or earlier if required. At 
that time, treatment efficacy can be determined in most cases. For larger 
lesions, more healing time may be necessary. Re-treatment can be considered 
upon the evaluation at 4 weeks post-treatment, but also later. A healing time of 
up to 10 weeks is admissible for lesions over 1.5 cm. For smaller lesions, 
healing time is in the order of 4–8 weeks. 
 
TUMOR RESPONSE EVALUATION 
 
Unidimensional, clinical or radiological, if reqired, in accordance with 
according to the RECIST criteria. 
 
QUALIY OF LIFE ASSESSMENT 
 
A pathology-dedicated questionnaire questionnaire was used. It was developed 
by means of physicians’ and patients’ interview, together with the creation of a 
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psychologist-guided patients focus group at our Institute, where most important 
disease’ related symptoms and patients’ reported outcomes were identified and 
discussed [42].  
 
TUMOR TISSUE ANALYSIS FOR TOLL-LIKE RECEPTORS 
 
TLRs study was performed on melanoma patients with in-transit metastases 
who underwent ECT. A first tumor tissue biopsy was collected before the ECT 
and another biopsy (of a not electroporated tumor nodule) was taken from the 
same patient after two days from ECT. Biopsies were immediately stored in 
liquid nitrogen until RNA extraction. We improved the extraction protocol in 
four consecutive steps because skin tissue was very difficult to process. The 
tested genes were the following: TLR3 (Toll-like receptor 3), TLR7 (Toll-like 
receptor 7), TLR9 (Toll-like receptor 9), TYR (Tyrosinase), GUS: beta-
glucuronidase (housekeeping); B-actin: beta actin (housekeeping). 
 
IN VITRO STUDY ON TUMOR SESITIZATION TO BLEOMYCIN 
 
The aim of the study was to evaluate the effects of the pre-treatment with BSO 
in combination with the ECT on melanoma cell lines. The hypothesis was that 
the depletion of intracellular GSH levels induced by the BSO pre-treatment of 
cells, in association with the local delivery of chemotherapeutic drug by 
electroporation (EP) can enhance the antitumor effects of the drugs. Selected 
cell lines (B16-F10 e SK-MEL-28) were cultured in order to firstly define their 
proliferative rate. In a second step, the cells were treated with increasing dose 
of chemotherapeutic drugs (bleomycin or melphalan) to identity the IC50 (the 
drug concentration which inhibited cell viability by 50% compared to drug 
untreated control cells) from semi-logarithmic dose-response curves. Thirdly, 
the EP was introduced in experimental set up, in order to verify the 
enhancement of chemotherapeutic drug cytotoxicity, evaluated as reduction of 
the IC50, compared to the absence of EP. After the identification of the dose-
  
 - 44 - 
response curves of bleomycin and melphalan on melanoma cell lines in the 
absence and in the presence of EP, the fourth step was to evaluate the effects of 
the pre-treatment of BSO in association with the subsequent drug treatment. 
Preliminary to this step is the analysis of the BSO effect on cell viability to 
exclude its cytotoxicity. Several doses of BSO were used to treat the cells, at 
different times. At the end of the treatments, cell viability was evaluated by 
using a spectrophotometric assay (WST-1). The identification of the optimal 
dose and pre-treatment time of BSO permits to perform the final step in which 
the ECT (EP + bleomycin or EP+ melphalan) was introduced after the 
pretreatment of the cells with BSO, in order to analyze and quantify the 
advantage obtained on anticancer activity  as a function of BSO pretreatment, 
EP and their combination.  
 
STATISTICAL ANALYSES 
 
Clinical trials were planned following a two-stage design (specified in the 
Results section for each study) to optimize patient’s accrual. Continuous data 
are presented as median (range). The association between parametric variables 
was assessed by means of the ANOVA on ranks test, Chi-square or Fisher’s 
exact test, according to data. Local progression-free survival (LPFS) was the 
interval from response achievement until local disease progression or the last 
follow-up. Survival analysis was calculated using Kaplan-Meyer’s method and 
the log-rank test was used for comparison. A P <.05 value was considered 
significant. Correlative analyses in the biological study were performed with 
Wilcoxon, T test and Chi-square test. Statistical analysis was performed with 
SigmaPlot Software, version 11.0 (Systat Software, Inc.).  
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RESULTS 
 
 
CLINICAL ECT 
 
MELANOMA [43] 
Of 89 patients evaluated, one declined treatment, one had medical 
contraindications to ECT and two were deemed too ill to tolerate anaesthesia. 
Population and tumour characteristics of the remaining 85 patients are 
summarized in Table 4. The disease had relapsed in 15 patients (18 per cent) 
after isolated limb perfusion and 10 (12 per cent) after radiotherapy. Twenty-
one patients (25 per cent) received conventional treatments at least 2 months 
after ECT: systemic chemotherapy in 13 and low-dose subcutaneous IFN in 
eight.  
 
Table 4. Descriptive characteristics of 85 patients diagnosed with disseminated 
superficial melanoma and treated with 226 electrochemotherapy sessions  
 
No. of patients* 
(n = 85)  
Age (years)† 70 (35–93) 
Sex ratio (M : F) 39 : 46 
Body mass index (kg/m2)† 27.6 (20.3–36.8) 
TNM stage  at enrolment in the 
study 
  IIIB 
  IIIC 
  IV 
 
32 (38) 
25 (29) 
28 (33) 
Involved anatomical area 
  Trunk 
  Upper limb 
  Lower limb 
 
   34 (40)‡ 
5 (6) 
46 (54) 
No. of skin metastases† 14 (1 to > 50) 
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Size of lesions (mm)†  11 (5–65)§ 
   5   7 (2.6) 
   6–10   41 (15.3) 
   11–20   108 (43.3) 
   21–30   60 (22.4) 
   > 30   50 (18.7) 
   Confluent 2 (0.7) 
Breslow thickness of primary 
melanoma (mm) † 
3.10 (1.20–9.00) 
 
*With percentages in parentheses unless indicated otherwise; †values are median (range). ‡Four 
patients also had metastases in head and neck region. §Total of 268 lesions. TNM, tumour node 
metastasis. 
 
Electrochemotherapy. The median number of ECT courses per patient was 3 
(range, 1–6). Twenty-four patients were treated with a single ECT, 15 with two, 
30 with three, 15 with four, two with five and two with six procedures. 
Bleomycin was administered systemically, locally or in combination in 117, 17 
and 92 sessions respectively. The median number of electrode applications was 
45 (6–135) per session. Electric currents had the following parameters, 
according to the electrode type: a train of four to eight pulses of 400–730 V, 
910–1000 V/cm, 100 µs duration and 5 kHz repetition frequency. The median 
registered electric current for a single application was 2.5 (0.6–9.2) A and pulse 
deliveries were adequate in 74 (87 per cent) of 85 patients.   
 
Treatment toxicity .Post-treatment pain was manageable with minor analgesics 
in 78 (92 per cent) of 85 patients. No ECT-related serious adverse events were 
reported. One patient experienced sinus bradycardia under general sedation 
(G2) and the procedure was interrupted. Eleven patients experienced some 
postoperative complications including syncope in four patients, 
nausea/vomiting (G1–G2) in eight and fever in four (G1–G2). Hospital stay 
lasted a few hours for 60 of the 85 patients. A skin reaction (G3) was present in 
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15 (18 per cent), seven (8 per cent) and six (7 per cent) patients at the 1-, 2- and 
6-month follow-up appointment respectively. None of the patient- or 
procedure-related factors analysed was predictive of severe skin toxicity. 
 
Tumour response and patient outcome 
Target lesions 
One month after ECT, 129 (48.1 per cent) of 268 target lesions had achieved a 
complete response and 118 (44.0 per cent) a partial response; the disease was 
stable in 16 (6.0 per cent) and progressive in five (1.9 per cent).  
  
Number of tumours  
Overall, 894 lesions were treated: a median of 11 (1 to more than 50) lesions 
per patient, with a median size of 24 (3–75) mm. Three-hundred and ninety-
three lesions (44.0 per cent) showed a complete response (Fig. 15), 492 (55.0 
per cent) an incomplete response or stable disease, and nine lesions (1.0 per 
cent) had progressive disease. Among the 85 patients, 1 month after ECT there 
were 41 complete responders (48 per cent; complete response on target and 
non-target lesions and no new lesions) and 39 partial responders (46 per cent; 
complete or partial response on target lesions and partial response or stable 
disease in non-target lesions and no new lesions). In three patients (4 per cent), 
there was no change in tumour size and in two (2 per cent) tumour progression 
had occurred. As all metastases were electroporated, it was not possible to 
ascertain whether there was any ‘bystander effect’ of ECT on untreated skin 
nodules. 
 
Local control and patient outcome 
After a median of 3 (1–6) ECT courses, the 2-year local  progression-free 
survival rate was 87 per cent. Follow-up lasted at least 2 years for 21 patients. 
Only six patients experienced recurrence within the ECT field, after a median 
interval of 16 (6–20) months. After a median follow-up of 26 (6–47) months, 
local tumour control (complete or partial response) was achieved in 42 of 48 
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surviving patients:  a complete response in 33 patients and a partial response in 
nine. During follow-up, new lesions outside the treatment field appeared in 
some patients, but local control was maintained by either single or repeat ECT 
in 24 and 61 patients respectively. Of 41 complete responders to the first ECT, 
ten patients were locally disease-free after a median follow-up of  22 (6–42) 
months. Nineteen patients received a second ECT course to treat new lesions a 
median of 6 (2–14) months after the first treatment. Sixty-one patients 
underwent a second ECT course. Thirty of 61 patients experienced a local 
complete response and 31 had a partial response. Fifty-three (87 per cent) of 
these patients maintained local control after a median follow-up of 18 (7–37) 
months. Of the 39 patients who had further treatment after a partial response to 
the first ECT session, 19 showed a complete tumour response and 20 a partial 
response to the second course. In this subgroup of patients, a total of 168 
lesions were retreated, of which 131 (78.0 per cent) showed a complete 
response and 37 (22.0 per cent) a partial response. Some patients affected by 
widespread skin metastases required up to three ECT cycles before obtaining a 
complete response and up to six cycles during follow-up to maintain local 
control. 
At the end of follow-up, seven patients were alive and disease-free, 41 were 
alive with disease and 37 had died owing to disease progression. Survival was 
longer in patients with limb metastases than in patients with tumour spread on 
the trunk: median 30 (95 per cent confidence interval 7 to 49) versus 25 (3 to 
33) months respectively (P = 0.002).     
 
Combination of electrochemotherapy with other treatments 
ECT was applied with limited toxicity in patients with disease relapse after 
either limb perfusion or radiation therapy. The combination of ECT and low-
dose IFN also proved to be well tolerated (Table S1of reference 43).  
 
Predictive factors for response 
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In multivariable analysis, a tumour size equal to or less than 3 cm and 20 or 
fewer lesions were associated with response to treatment. Prognostic variables 
for local control in the univariable analysis were the number of lesions, ECT 
cycles and electrode applications. Cox proportional hazards analysis showed 
that only increasing number of electrode applications at the first treatment (P = 
0.041) and increasing number of ECT cycles (P = 0.005) were independent 
prognostic variables. Breslow thickness of the primary melanoma and location 
of the tumour lesion (limbs versus trunk; P = 0.002) were the best predictors of 
overall survival.  
 
Discussion. Bleomycin is ineffective for systemic therapy of malignant 
melanoma. Local application  of brief electric pulses enhances the delivery of 
bleomycin by temporary cell membrane permeabilization. In patients, ECT not 
only magnifies drug cytotoxicity but also produces antitumour vascular effects: 
transient vasoconstriction at the arteriolar level, which leads to drug retention in 
the tumour and also endothelial cell destruction. The synergism of these 
mechanisms explains the favourable results in the treatment of melanoma and 
non-melanoma skin cancers. The present findings confirmed that, even with 
repeated application, ECT is well tolerated, with limited, mainly 
dermatological, toxicity. 
The effectiveness of ECT was demonstrated by the complete response at first 
application in almost half of 268 tumour lesions that were refractory to other 
treatments. This is comparable to most previous findings. The administration of 
a second ECT to patients with an initial  partial response increased the local 
complete response rate to 78.0 per cent (131 of 168 nodules). The 
administration of up to six treatments resulted in a 2-year local tumour control 
rate of 87 per cent. After a median follow-up of 26 months, only six (7 per 
cent) of 85 patients experienced a relapse within the ECT field. The median 
time to local recurrence in the ECT field was 16 months, thus ensuring disease 
stabilization in a palliative setting. Superficial local tumour control was 
achieved in 42 of 48 surviving patients. Although tumour control could have 
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been confounded by the administration of subsequent treatments, only a quarter 
of patients received additional systemic therapies; no differences in local 
control and survival were found between patients who received further 
treatments after ECT and those who did not (data not shown).  
The outcome of patients with disease relapse after limb perfusion or 
radiotherapy and in patients receiving adjuvant low-dose IFN was analysed in 
regard to some previous results. An interesting, although preliminary finding, 
was the favourable outcome for these subgroups.  This is important because of 
the concern that previous radiation could reduce bleomycin diffusion and 
electric field application. Finally, it could be intriguing to verify whether the 
antiangiogenic activity of low-dose IFN might improve the well known 
antivascular effect of ECT. 
The association between tumour response and tumour size confirms previous 
observations of lower tumour response rates among larger tumours. The 
correlation between response and the number of tumour nodules raises the 
possibility that some lesions might have been electroporated beyond the 
recommended 20-min bleomycin washout. In the future, technical advances 
may allow the electroporation of more tumour lesions within the 20-min 
window.      
The increasing number of electrode applications and increasing number of ECT 
cycles were the only predictors of superficial tumour control. This finding 
justifies multiple electrode insertions during a single procedure and the 
application of more ECT courses in patients with large and/or diffuse 
metastases. These technical issues might be overcome by the availability of 
newly designed electrodes. 
In this series, patients with leg metastases were found to have a more 
favourable prognosis than those with lesions located in the trunk. No difference 
was observed between patients with superficial disease versus those with both 
superficial and visceral disease. This observation could influence the selection 
of patients for ECT; patients with few and small limb metastases, regardless of 
visceral disease, could be considered more suitable for treatment. 
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The present investigation has a number of limitations; it was carried out in a 
single centre, the patient cohort was relatively small, technical parameters were 
assessed only at the first procedure, and the study was conducted before the 
introduction of new therapies such as vemurafenib and ipilimumab. 
Nevertheless ECT proved to be highly active against metastases that were 
refractory to previous chemotherapy.  
ECT leads to long-term stabilization of widespread superficial melanoma. From 
a clinical point of view, the present results suggest that patients with 20 or 
fewer skin metastases, smaller than 3 cm in diameter, particularly when 
confined to the lower limb, have a high local response rate, with disease control 
and favourable survival.  
 
 
BREAST CANCER [44] 
Patients’ characteristics at baseline. Thirty-seven consecutive patients with 
refractory CWR were enrolled from December 2006 through September 2011. 
Two patients were excluded for the presence of a subcutaneous port-a-cath on 
the tumor-involved CW. Patients’ characteristics, are listed in Table 5.  
 
 
Table 5. Patient characteristics 
Patient characteristics 
T stage of primary breast cancer  
T1 / T2 / T3 / T4 5 / 14 / 8 / 8 
N stage  
N0 / N1 / N2 / N3 6 / 10 / 13 / 6 
Lymphovascular invasion (%) 11 (31.4) 
  
Time (months) to 1st recurrencea, 
median (range) 
 
31 (9-64) 
Time (months) to 1st CW recurrence,  
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median (range) 33 (9-58) 
Time to referralb for ECT treatment  
median (range) 
 
10 (3-45) 
  
Agec, median (range) 67 (35-88) 
Karnofsy PS, median (range) 90 (70-100) 
Patients with comorbiditiesd (%) 28 (80)  
Clinical stage at accrual   
IIIB /  IIIC / IV 6 / 5 / 24 
Disease extension 
superficial / superficial plus deep  
 
12 / 23 
Size (mm) of skin metastases, 
median (range) 
 
20 (10-220) 
Type of metastases 
nodule / plaque 
 
15 / 20 
ER status positivee 24 (68.6)  
PgR positivee 24 (68.6)  
Her2 positivef  10 (28.6)  
Triple negative 5 (14.3) 
CW skin ulceration (%) 9 (25.7) 
CW bleeding (%) 4 (11.4) 
 
Abbreviations: CW, chest wall; ER, oestrogen receptor; PgR, progesterone receptor; PS, 
performance status  
a
  Breast cancer recurrence in any site.  
b
  Time interval from the diagnosis of skin metastases to the first visit to accrual in the study. 
c
  Age at the time of ECT treatment.  
d
  The most frequent comorbidities were: pain (12/35 patients); hypertension (11/35); upper  
   limb oedema (10/35); fatigue (10/35); heart failure (9/35); chest wall skin ulceration.  
   (9/35); anorexia (9/35); anorexia (7/35); diabetes (6/35). 
e
  Oestrogen and progesterone receptors were considered positive with at least 30% of  
   stained cell at the immunohisthochemical assay. 
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f
  HER-2/neu amplification was evaluated according to international guidelines [www.nccn.org, 
downloaded on   
   October 2006]. 
 
Electrochemotherapy. Overall, 62 ECT courses were delivered (median 2 ECT 
/patient, range 1-3). Fourteen patients (40%) received a single ECT, 15 (42.8%) 
received 2 ECTs and 6 (17.2%) 3 ECTs. The treatment was delivered according 
to the protocol in all cases and CW metastases were encompassed within the 
ECT-field. The procedure lasted a median of 25 minutes (range, 15-35) and the 
median hospital stay was 1 day (range, 1-3). 
 
Treatment toxicity. No serious ECT-related adverse events were reported. One 
patient developed a G5 pulmonary embolism four weeks after the second ECT 
and died nine weeks thereafter as a consequence of respiratory distress 
syndrome; this event was judged as unrelated to ECT. After ECT, six patients 
(17.1%) experienced fever (G1-2) and 2 patients (5.7%) reported uncontrolled 
pain. Seven patients experienced other early complications, including 
nausea/vomiting (G1-2, n=4;), syncope (n=1) and urticaria (G1, n=1) that did 
not modify the clinical course. 
 
Pain. After each ECT course, patients’ reported pain scores improved in the 
interval between 1- and 2-month follow-up, although worsened with the 
increasing number of ECT courses. One week after the first ECT, 28 patients 
(80%) reported pain control (“no pain” or “mild pain”) and after one month, 
this number rose to 33 (94%). One-week and one-month pain control after each 
ECT cycle is detailed in Figure 2. 
 
Dermatological toxicity. A G3 skin ulceration was present in 5 (14%) and 2 
(6%) patients at the one- and two-month control, respectively, following the 
first ECT (Fig. 3). These patients were among the 9 patients (25.7%) who 
already presented ulcerated skin metastases at the time of accrual. The 
percentages of patients with skin ulceration and/or pigmentation after each ECT 
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cycle are detailed in Figure 3. Finally, 3 patients (8.5%) reported a G1 transient 
alopecia, likely induced by systemic bleomycin administration.   
 
Tumor Response (Target Lesions). A total of 516 metastases were 
electroporated (median 15, range 1-50), response was assessed on 196 target 
lesions (median size 20 mm, range 10-220). Two months after the first ECT, an 
objective response was reported in 32 of 35 patients (91.4%). Nineteen patients 
had CR (54.3%, 95% C.I. 38%-84%), hence satisfying the study primary 
endpoint. Thirteen patients (37.1%) had PR and three (8.6%) were stable. No 
local tumor progression occurred. 
Among the 19 complete responders at first ECT, 10 patients were still local 
disease-free at a median follow-up of 32 months (range, 6–52). One patient, 
who locally relapsed after 16 months, was retreated, achieving a CR that was 
maintained at 12-month follow-up. Of the 9 remaining patients, only 6 received 
further ECT for NL (developed after a median of 8 months, range 3–14). After 
the second ECT, the local response was complete and partial in 4 and 2 
patients, respectively. Five of these patients developed additional NL and have 
been scheduled for retreatment.    
 
In the subgroup of patients (n=16) who reported a PR or SD, 14 developed NL. 
Seven patients underwent a single retreatment, while five patients (two with 
triple negative BC) required up to a total of three ECTs. At the end of the 
follow-up the local status was as follows: 5 CR, 6 PR, 1 SD, 4 progressive 
disease (PD). At the last follow-up, NL were present in 11 of 16 patients, so an 
“effective CW control” (CR or PR on electroporated metastases and absence of 
NL) was achieved only in 2 patients with triple negative disease. 
There were no significant associations between patients’ clinical-pathological 
characteristics and local response (Table 3). After a median follow-up of 32 
months (range, 6-53), local tumor control (CR plus PR) in the electroporated 
metastases was obtained in 30 of 35 patients (85.7%, 22 with CR and 8 with 
PR). 
  
 - 55 - 
 
Local progression-free survival. The median follow-up was 32 months (range, 
6-53) and 3-year LPFS was 81%. In the five relapsing patients, the median time 
to local failure was 18 months (range, 9-22). LPFS was independent on the 
investigated clinical-pathological parameters. 
 
New lesions-free survival. Overall, 23 of 35 patients (65.7%) developed NL 
(Fig.4b), after a median time of 6.6 months (range, 2.3-29.5). NL occurred in 
9/19 (47.4%) of complete responders and in 14/16 (87.5%) patients who 
achieved PR/SD (P=.029). The NLFS was significantly related to the following 
parameters at log rank analysis: number of skin metastases, degree of tumor 
spread on the CW, response to the first ECT and type of systemic treatment 
post ECT. The number of metastases and the degree of tumor spread showed 
significant hazard ratios with the Cox proportional risk model. 
 
An “effective CW control” (e.g. both local control and freedom from NL) was 
achieved in 12 of 35 patients (34.3%), by means of one (n=3 patients), two 
(n=8) or three ECT cycles (n=1) (Figure 6). 
 
Overall Survival. Six patients (17.1%) developed distant metastases (median 
time 16 months, range 7-28.3). The estimated 3-year OS rate was 58% (median, 
39 months). The OS was significantly higher in patients with longer disease-
free interval from the primary BC (P=.047). There was no significant difference 
according to primary BC node status (P=.71) and disease extension (P=.65).     
 
Discussion. The present study reports, for the first time, the prospectively 
collected data on 35 BC patients treated with ECT for CWR after mastectomy. 
In this experience, bleomycin-based ECT showed a significant activity in the 
treatment of metastases that were refractory to CW re-irradiation and different 
lines of systemic therapy, in fact more than half of the patients obtained a local 
CR at the first application. This finding is comparable with the results on BC 
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retrievable from mixed series of heterogeneous cancer patients treated with 
ECT.  Remarkably, after a median follow-up of 32 months, only 5 out of 35 
patients experienced a local failure (median time 17.6 months), resulting in a 3-
year LPFS of 81%, that could be regarded as a satisfying CW control, at least in 
the palliative setting. We were not able to detect any difference in tumor control 
according to the patients’ clinical-biological features, probably due to the small 
series, but also to the high ECT activity. 
ECT antitumor effect is restricted to the volume of electrode application and 
this is documented by the occurrence of NL even in two thirds of our patients, a 
critical aspect that should be addressed in future clinical investigations. 
Notably, we reported a significantly lower incidence of NL in those with fewer 
and contained CW metastases together with patients who achieved CR. Also 
endocrine treatment after ECT was associated with a lower incidence of NL 
compared to systemic chemotherapy, but this finding could be explained by the 
intrinsic favorable disease natural history of endocrine receptor positive BC. 
Finally, HER2 expression did not impair the activity of ECT that remained an 
appreciable therapeutic option also in patients with more aggressive features 
(e.g. triple negative BC) to maximize the opportunity for local tumor control. 
Although ECT showed satisfactory activity on refractory tumors, as many as 23 
patients (65.7%) developed NL. We can desume that in these patients systemic 
treatments were not active, despite that ECT had a curative effect on the 
electroporated lesions. However, since after ECT the patients with more than 
10 metastases received preferentially chemotherapy and those with 10 or less 
metastases endocrine therapy, further clinical investigation is needed to confirm 
our results, in order to select patients who are likely to achieve a CR after a 
single ECT and are less prone to develop NL, thus sparing them from repetitive 
treatments. According to our experience, retreatments with ECT should be 
limited to selected cases, due to the observation of increased patients’ reported 
pain and risk of dermatological toxicity by the increasing number of 
applications. For instance, after the third ECT cycle no patient reported to be 
completely pain-free, either at one- or four-week assessment. Skin toxicity, 
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instead, could have also been favored by the variable pre-ECT radiation 
exposure (ranging from 72 to 116 Gy), in fact 9 out 35 presented with ulcerated 
metastases at the time of accrual. In this trial ECT did not improve patients’ 
prognosis, but these negative data of survival in our opinion do not limit the 
applicability of this treatment in the daily practice because, also in presence of 
visceral metastases, ECT may reduce the morbidity of uncontrolled superficial 
disease spread. In this setting, the benefits of ECT are the shortness of 
treatment duration (the procedure lasts a maximum of 20-30 minutes), easiness 
of application, brief hospitalization (generally 1-2 days), high activity rates, 
repeatability, possibility of safe combination with other treatments and limited 
systemic toxicity. However, our work shed further light on some drawbacks 
that deserve consideration. First, ECT does not allow the treatment of lymph 
nodes or skin metastases near to an installed port-a-cath reservoir for 
intravenous chemotherapy, because the insertion of the needle electrode may 
injure nerves, vascular structures or the subcutaneous catheter. Second, more 
data on ECT early-, but also on long-term toxicity profile, are awaited. Third, 
the ECT treatment modalilities for CWR are not completely standardized, in 
fact the electrode insertion is operator-dependent and tailored to the clinically-
detectable metastases. Fourth, there are no comparative studies with standard 
therapeutic approaches. Finally, since it is unclear if ECT provides a clinical 
benefit to all cases of CWR, there are no shared criteria for patients selection. 
 
ECT is a promising treatment option for different tumors and has proved 
effective in the multidisciplinary treatment of advanced malignant melanoma, 
both by administering bleomycin or cisplatin. Surprisingly, the therapeutic 
properties of these drugs seems to be electroporation-improved also in BC, for 
which they have no or limited role in standard chemotherapy regimens.  
Recently, an increasing number of reports highlight the feasibility of ECT in 
this cancer. Although the clinical experience is smaller compared to melanoma, 
the preliminary results are encouraging. In a report from Cork Cancer Centre, it 
has been shown that ECT, by means of multiple applications, can locally 
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control widespread CWR. In the patient reported by Whelan et al, it is 
noteworthy that repetitive courses of ECT were well tolerated and metastases 
that were refractory to conventional therapies shrinked after ECT 
administration. In our first clinical study on 11 heterogeneous BC patients, we 
faced with different grades of superficial tumor spread on the CW. ECT proved 
to be active, but in the thin soft tissues of the CW after mastectomy, the needle 
electrode insertion was incomplete, consequently the applied electric voltages 
were often lower than that recommended for an effective 
electropermeabilization, raising some concerns on the feasibility of ECT in 
these patients.  
More recently, the comprehensive ECT clinical experience on CWR from BC 
has been reviewed by Sersa et al . The authors analyzed eight clinical trials 
from 1996 to 2009, none of which was specifically designed for BC. From the 
collected data, the overall response rate was 89%, complete 59%. Although 
encouraging, these results were obtained by means of different treatment 
protocols, either for the chemotherapeutic agents (bleomycin or cisplatin) or 
their delivery route (intravenous or intratumoral). Finally, only 37 out 49 
patients considered in this review were treated according to the European 
Standard Operating Procedures of Electrochemotherapy.   
 
Radiation therapy remains the reference approach for the treatment of CWR. It 
allows a full thickness CW treatment as well as the simultaneous targeting of 
the lymph nodes. However, it is a common finding that a number patients are 
not suitable for a full dose treatment, due to previous radiation exposure or 
comorbidities, particularly when cardiotoxic agents are also used. In our 
opinion, these two treatment approaches may be not just compared, but also 
combined. Two intriguing preclinical studies from the Institute of Oncology of 
Ljubljana support a radiosensitizing effect of both electroporation-administered 
cisplatin and bleomycin in different types of tumors, so that the application of 
ECT followed by irradiation could be envisioned also in breast tumors.  
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In conclusion, although ECT does not enjoy enough evidential support to 
represent an alternative to conventional treatments for CWR from BC, in this 
series it proved active in re-irradiated tumors that were refractory to several 
systemic treatments. Unfortunately, BC deposits permeate CW dermal 
lymphatics and blood vessels and are prone to grow outside the electroporated 
areas, forcing therefore many patients to multiple ECT administrations. 
Although only approximately a third of patients (12 out of 35) achieved an 
“effective CW control”, ECT has the potential to be applied earlier in the 
clinical course of CWR, in fact, according to our data, the patients with fewer, 
less scattered and complete responding metastases are less likely to develop 
NL, thus avoiding additional ECT administrations. The patients with tumor 
partial response or NL can still be managed with further ECT, but experience 
an increase of pain and dermatological toxicity which require a pressing 
refinement of the protocol for their clinical management.  
 
SOFT TISSUE SARCOMAS (Abstract of the submitted paper) 
 
BACKGROUND: Electrochemotherapy (ECT) had shown strong 
cytoreductive effect in soft tissue sarcomas (STS) animal models. The toxicity, 
activity and feasibility of ECT were explored in a two-stage, phase II clinical 
trial. 
METHODS: Thirty-four patients with superficially-recurrent (maximum 3 cm-
deep) STS of any histotype ineligible to conventional treatments received one 
to four cycles of intravenous bleomycin and percutaneous tumour 
electroporation, according to the European Standard Operating Procedures of 
Electrochemotherapy (ESOPE). 
RESULTS: Tumour response after the first ECT, assessed on 71 target lesions 
(median size 4 cm, range 2-12 cm), was as follows: 32.3% complete, 52.9% 
partial, and 14.7% stable (Fig. 16). Fifteen patients received up to 4 ECTs for 
incomplete response or disease progression, although re-treatment did not 
significantly improve response rates (P=.205). Median follow-up was 19.3 
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months and two-year local control rate 72.5% (Fig. 17). Median time to 
progression was 5.1 months. Tumour response (P=.041) and control (P=.047) 
correlated with tumour grade.  Toxicity consisted of manageable G3 skin 
ulceration and soft tissue necrosis in 35% and 23% of patients, respectively. 
The accuracy of electrode placement was 47.1%, the adequacy of 
electroporative current 85.3%.  
CONCLUSION: ECT is a new treatment option for patients with recurrent 
STS. ECT technique deserves further investigation to contain local toxicity and 
improve tumour voltage delivery. 
 
 
HEAD AND NECK CANCERS (Abstract of the submitted paper) 
 
Objectives. To evaluate the effectiveness of electrochemotherapy (ECT) in the 
treatment of head and neck cancer. 
Methods. Electronic records of patients treated with ECT between 2006 and 
2012 were reviewed. They included patients with head and neck skin tumors 
(HNSTs) and oral cavity/oropharyngeal squamous cell carcinomas (OC/O-
SCCs). Tumor characteristics and ECT parameters were tested for correlation 
with outcome.  
Results. There were 42 patients. Three patients underwent cisplatin-ECT and 1 
patient bleomycin (BLM)-ECT with plate electrode, the remaining 39 patients 
received BLM with needle electrode tumor electroporation and were included 
in the analysis. Twenty-seven (69.2%) had HNSTs, 12 (30.8%) OC/O-SCCs. 
Median tumor size was 35 mm. BLM was administered intratumourally, 
intravenously or in combination in 7, 7 and 25 patients after local anesthesia, 
sedation or general anesthesia in 16, 13 and 10 patients, respectively. Overall 
response was 59%, complete 38%. Complete response correlated with tumor 
presentation (primary 84%, recurrent 16%, P<.001), size (≤2 cm 73%, >2cm-≤ 
4cm 26.3%, >4cm 14%, P=.022) and route of BLM administration 
(intratumoral 100%, intravenous 29%, P=.024). Basal cell carcinoma (BCC) 
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showed a trend for higher response compared with squamous cell and 
adenocarcinoma (75%, 26.3% and 33%, P=.071). HNSTs and OC/O-SCCs 
showed comparable complete response rate (41 and 33%, P=.734) and local 
control (1-year local progression-free survival [LPFS], 51 and 44% P=.887). 
Median LPFS was 12.5 months, 
Local control was higher in patients with BCC (P=.029), and in patients who 
did not received previous chemotherapy (P=.027) or radiation (P=.063). 
Conclusions. BLM-ECT is active in small-size, primary, HNSTs (particularly 
in BCC) and OC/O-SCCs. The patients with BCC and those who did not 
received previous chemotherapy or radiation achieve higher local control. 
 
 
DEEP SOFT-TISSUE TUMORS (ongoing study) 
 
The preliminary report of this ongoing study has includes 20 patients (of the 38 
necessary by the study design) and is focused on feasibility and activity data. 
Overall, the procedure seems more technically demanding, in fact the median 
time was 60 minutes (range, 25-90). This is due to the need of accurate 
electrode placement in deep tissues (under US guidance) during the procedure, 
and a slightly more management of the pulse generator to achieve a tailored 
electric field to each single tumor.  
The response rate of ECT administered by means of the new pulse generator 
and long needle electrodes, was 100% in melanoma patients and 89% in non-
melanoma patients (soft tissue sarcomas and other, rarer soft tissue 
tumors/metastases). Six melanoma patients maintained local control after 1-
year follow-up.  
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IN VITRO STUDIES 
 
TOLL-LIKE RECEPTORS INDUCTION 
 
We collected the tumor speciment of 34 melanoma patients who underwent 
ECT for in-transit metastases. RNA levels of TLR-3, TLR-7 and TLR-9 
between pre- and post-ECT were compared. There were no significant 
differences in gene expression pre versus post ECT treatment in metastatic 
melanoma patients (Fig. 18 ). 
 
TUMOR SENSITIZATION TO BLEOMYCIN 
 
Dose response curves were identified for both the cell lines (B16-F10 and SK-
MEL 28) in presence of BLM alone and in presence of BLM plus electric 
pulses (EP) were calculated and also the IC50. Of note, the association of EP to 
BLM decrease the IC50 in both cell lines (Fig. 19 and 20). 
Pretreatment of melanoma cell lines with BSO, even at different 
concentrations, did not increase the citotoxicity of bleomycin and electric 
pulses (Fig. 21).  
In parallel experiments, electric pulses have been tested also in combination 
with melphalan (L-PAM), an alkylating agent that is used in the treatment of 
melanoma. Interestingly, the association of the electric pulses seems to increase 
to cytotoxic action of melphalan on both melanoma cell lines (Fig. 22). 
Moreover, cell exposure to low concentrations of L-PAM, in presence of both 
EP and BSO pre-treatment, was associated with the higher cytotoxicity in SK- 
MEL 28 cell line (Fig. 23).   
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DISCUSSION 
 
ECT proved to be an active antitumor treatment in all the tumor histotypes in 
which was tested (melanoma, breast cancer, soft tissue sarcomas, head and 
neck cancer). The overall response rate was 94, 91, 85, 59%, respectively. 
 
 This promising activity data translated in variable outcomes as to local tumor 
control, according also to disease stage and the underlying prognosis. Many 
patients with skin metastase, infact, have a dismal prognosis due to high tumor 
aggressiveness and when tumor skin infiltration occurs, have generally 
hexausted multiple treatment options. 
 
Hence, patients selection is of paramount importance in a treatment, such as 
ECT, that is mainly applied in advanced stage disease patients. In this way, our 
findings from melanoma and breast cancer patients, could help, to individuate 
possible reliable predictive factors in order to select for ECT only the patient 
who benefit most from it. The collection of patients’ functional outcome 
together with patients’ quality of life data will give a useful and complementary 
point of view, especially when the rate between benefit and morbidity is not yet 
clearly established, as in head and neck cancers treatment. 
 
However, even thanks to the possibility of being easily repeated, ECT ensured 
the sustained local progression-free survival rates, ranging from 81 to 87%. 
Survival data in head and neck cancer are more controversial and, up to now, 
homogeneous study populations are lacking. However, our preliminary 
experience showed the feasibility of treatment application also to mucosal 
squamous cell carcinomas of small size and located in the proximal side of the 
oral cavity and oropharynx.. 
 
Through our phase II trial performed on large and deep soft tissue tumors, we 
showed that the combination of electric pulses and chemotherapy works also on 
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big size tumors, even thouth different pulse parameters with higher amplitude 
are necessary and a specific training for the treating physician is mandatory. 
 
Possible strategies for improving ECT effectiveness have been explored, i.e. 
immune system reaction (in 34 melanoma patients) and tumor sensitizing to 
BLM by means of BSO pre-treatment (in melanoma cell lines). 
 
Contrary to a preclinical report on an animal model, we were not able do 
demonstrate an induction of the TLRs RNA in tumor biopsie performed 48 
hours after ECT treatment, however a diffuse lymphocyte infiltration was 
associated with a higher response rate. Although the patients respected a wash-
out from other treatments before ECT, the heterogeneity and extent of previous 
anticancer therapies may have influenced our results. 
 
Finally, BSO pretreatment seems not to sensitize two melanoma cell lines to 
BLM. On the contrary and interestingly, it appears to increase the cytotoxic 
action of melphalan, particularly when in association with electric pulse. This 
findings open the possibility to explore melphalan chemotherapy, already used 
in the setting of the isolated limb perfusion, in combination with tumor 
electroporation and BSO pre-treatment. Further in vitro experiments are 
necessary to individuate possible ideal treatment parameters in order to move to 
clinical tests in melanoma patients.     
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FIGURES 
 
 
 
 
 
 
Fig. 1 Cell in an electric field. The induced transmembrane potential is 
maximal at the poles of the cell in accordance with Schwan’s equation 
(Introduction section). Electroporated area is presented with dashed line. 
 
 
 
 
 
 
Fig. 2 Fraction of electroporated cells is increasing with increasing number of 
applied pulses. Abbreviations: E, electric field strength; T, pulse duration, N, 
number of applied pulses 
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Fig. 3 Increasing the pulse amplitude results in larger area of membrane with 
smaller extent of electroporation, while increase in pulse number or duration 
does not affect the membrane area but increases the extent of electroporation 
 
 
 
 
Fig. 4 Introduction of small and large molecules by electroporation. (A) 
Introduction of small molecules takes place during and predominantly after the 
pulse. Electroporation of the cell membrane is asymmetrical and occurs first at 
the anode side (small grey arrows). (B) Introduction of DNA into the cell. DNA 
must be present before electric pulses are applied. The initial step is DNA 
adsorbtion to the cell membrane, which takes place in the cell membrane facing 
cathode (small grey arrows). (C) When DNA is added after the pulse 
application it cannot be introduced into the cell. 
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Fig. 5 Effect of electric field orientation on electroporation of different cell 
sizes and shapes. (A) Electric field parallel to elongated cell. (B) Electric pulse 
amplitude is increased. (C) Orientation of electric field is changed. (D) Electric 
pulse amplitude is increate. 
 
 
 
Fig. 6 Formation and effects of cisplatin. Cisplatin undergoes aquation to form 
[Pt(NH3)2Cl(OH2)]+ and [Pt(NH3)2Cl(OH2)2]2+ once inside the tumor cell. 
Cisplatin induces inter- and intra-strand nuclear DNA crosslinks, binds to 
mitochondrial DNA, causes endoplasmic stress, interacts with phospholipids 
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and phosphatidylserine in membranes, disrupts the cytoskeleton and affects the 
polymerization of actin. These biological consequences are responsible for 
tumor cytotoxicity. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 Formation and effects of activated bleomycin. Activated bleomycin can 
be formed by bleomycin binding to Fe(II), followed by oxygen binding and 
reduction by a reductant. This intermediate (black box) has a half-life of several 
minutes at 4°C. It can destroy itself, oxidize phospholipids, hydrolyze amide 
bonds of proteins and initiate chemical and sequence-specific cleavage events 
on RNA and DNA. These biological consequence and dsDNA cleavage are 
responsible for tumor necrosis. 
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Fig. 8  Model for electroporative channel development. Under the influence of 
an electrical field, the distribution of ions adjacent to the inner surface of cell 
membranes is proposed to be altered, resulting in a series of membrane 
alterations that predispose to pore formation. 
 
 
 
 
Fig. 9 Therapeutic efficacy of electrochemotherapy on cutaneous and 
subcutaneous tumour nodules (n=171) of different histology in 41 patients 
(results of the ESOPE study). 
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 Fig. 10 Local tumour control curves for ECT with bleomycin given 
intravenously (ECT–BLM i.v.; 86 nodules) or intratumourally (ECT–BLM i.t.; 
41 nodules), and cisplatin given intratumourally (ECT–CDDP i.t.; 44 nodules). 
Local tumour control rate was estimated with the Kaplan–Meier method, and 
the difference between the curves was analyzed by means of the log-rank test. 
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Fig. 11 Electrochemotherapy project overview with milestones and deliverables 
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Fig. 12 Eletrode models: plate (left), needle with linear array (in the middle) and 
needle wiyh an hexagonal array.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 Electrode connected with their handle 
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Fig. 14 Cutaneous metastases in three patients treated with electrochemotherapy 
(ECT). a Large subcutaneous recurrent metastasis of the chest wall in a patient 
previously treated with wide surgical excision (left panel; baseline computed 
tomogram shown below). A complete response was observed 2 months after a 
single ECT session. Intermediate clinical follow-up was at 6 months (centre panel). 
Additional cytotoxic chemotherapy and interferon therapy was administered for 
lung metastases after 18 months. The patient was disease-free at the last clinical and 
radiological examination at 42 months (right panel). b Disseminated lesions of the 
trunk at baseline (left panel). Treatment with ECT led to a partial response at 
intermediate follow-up at 1 month (centre panel). There was complete and long-
lasting cutaneous remission after the second ECT cycle, and the patient was alive 
with disease at last follow-up after 37 months (right panel). c Multiple bulky lesions 
of the trunk at baseline (left panel). Treatment by three ECT cycles led to a 
complete response at intermediate follow-up after 12 months (centre panel) with 
superficial tumour control at 42 months (right panel). Each jagged arrow (  ) 
represents a single ECT session. 
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Fig. 15 Examples of complete response after electrochemotherapy in soft tissue 
sarcoma patients (Kaposis’s sarcoma and leiomyosarcoma). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16 Kaplan-Meier estimate of local progression-free survival after ECT in 
patients with recurrent soft tissue sarcomas. 
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Fig. 17 TLR-3, TLR-7, TLR-9 RNA expression levels in cutaneous metastases of 
melanoma patients, sampled before and after ECT* (at 48 hours) in 34 melanoma 
patients. * The tumor biopsied at 48 hours was not electroporated during ECT 
session. 
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Fig. 18 Dose response-curve of B16-F10 melanoma cell lines in presence 
of bleomycin alone or after the combined treatment of bleomycin and electric 
pulses. IC50 BLM >> 100 nM; IC50 BLM+EP= 0.5 nM 
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Fig. 19 Dose response-curve of SK-MEL 28 melanoma cell lines in presence 
of bleomycin alone or after the combined treatment of bleomycin and electric 
pulses. IC50 BLM >> 100 nM; IC50 BLM+EP= 100 nM 
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Fig. 20 Dose response-curve of SK-MEL 28 melanoma cell lines exposed to 
bleomycin in four different settings: 
- no BSO pretreatment and no electric pulses (EP) 
- no BSO pretreatment, si EP 
- si BSO, no EP 
- si BSO, si EP 
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Fig. 21 Dose response-curve of B16-F10 melanoma cell lines exposed to melphalan 
(L-PAM) alone and L-PAM plus electric pulses. 
IC50 L-PAM=2.7nM; IC50 L-PAM+EP=7nM 
 
 
 
 
Fig. 22 Dose response-curve of SK-MEL 28 melanoma cell lines exposed to L-
PAM (for 2 hours) in four different settings: 
- no BSO pretreatment and no electric pulses (EP) 
- no BSO pretreatment, si EP 
- si BSO, no EP 
- si BSO, si EP 
